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Measuring population immunity to infectious diseases is an important metric to assess the 
potential for outbreaks and target interventions. Vaccination coverage is typically used to 
approximate population immunity levels, but the most direct measure is to collect biospecimens 
and test antibody levels in the population. This method of conducting serological surveillance 
can monitor progress towards measles and rubella elimination and flag immunity gaps to target 
for vaccination. Serosurveys have been conducted for both measles and rubella viruses, primarily 
in developed countries due to the costs, logistics, laboratory requirements, and analysis 
techniques that make serological surveillance complex. 
This dissertation addresses serosurvey design topics including community acceptance, 
cost estimates, and data analysis issues when estimating seroprevalence from different survey 
designs. We use the context of two serosurveys conducted to monitor population immunity 
before and after a measles-rubella vaccination campaign in Zambia. First, we evaluated barriers 
and facilitators to serosurvey participation using quantitative and qualitative data. Qualitative 
data from data collectors who participated in a measles-rubella serosurvey and caregivers at 
health facilities identified interpersonal relationships and serosurvey design issues as key barriers 
and facilitators to participation. Provision of information ahead of the serosurvey to answer 
questions related to blood collection and communicating through a trusted source, such as the 
community health worker, were particularly important.  
In the second aim, we captured the cost of implementing serosurveys. We estimated that 
up to two-thirds of costs could be saved by nesting a serosurvey in an already planned 
vaccination coverage survey. Identifying what contributes to serosurvey costs can help identify 
ways to reduce cost to make them more accessible to low- and middle-income countries.  
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Finally, in the third aim we evaluated the impact of the vaccination campaign in Southern 
province, Zambia. The pre and post-campaign serosurveys demonstrated significant increases in 
seroprevalence of antibodies to measles and rubella, highlighting the impact of the vaccination 
campaign. Comparing the serosurveys required survey weighting and direct adjustments to 
account for selection bias, specimen types and laboratory test kits. Characterizing the 
acceptability, cost and analytic challenges can help improve the design and implementation of 
serological surveys to meet programmatic goals. 
 
 
Committee of Readers 
Advisor: Daniel Salmon, PhD; Professor -Department of International Health 
William J Moss, MD; Professor -Epidemiology Department 
Kyla Hayford, PhD; Assistant Scientist -Department of International Health 
Christopher D Heaney, PhD; Associate Professor -Environmental Health 
Alternate: Rupali Limaye, PhD; Associate Scientist -International Health 





I would like to acknowledge the staff in Zambia for their collaboration, guidance during 
data collection activities, and implementation of the research. I would especially thank Simon 
Mutembo for providing ongoing communication with the Ministry of Health and in-country 
context to carry out this project. I also want to thank the study staff both in the field collecting 
data as well as in the laboratory testing specimens. The partnership and collaboration with the 
Ministry of Health, Macha Research Trust, University Teaching Hospital, and Tropical Disease 
Research Center made this dissertation possible. 
Next, I would like to thank Bill Moss and Kyla Hayford for bringing me on to their 
project from the beginning, for providing me with the opportunity to work in Zambia, and for all 
the technical guidance, opportunity for professional growth and comradery they have provided. 
Thank you to the Bill and Melinda Gates Foundation for the funding support the project. I would 
like to acknowledge my academic advisor Dan Salmon for his professional advice and academic 
support throughout the PhD. Thank you to all those who contributed to, provided technical 
advice for data analysis, or reviewed the manuscripts.  
A very special thank you to my husband for his love and support during my PhD and 
especially the dissertation process, and for believing in his “investment.” And finally, a most 
heart-felt sense of gratitude to my sisters and especially my parents who instilled a desire for 
learning in us at a young age. They have always supported my education and believed that I 
could do anything I set my mind to. Their belief in helping others through their careers, taking 
me on rounds in the hospital, and exposing me to the value of research have shaped me and my 
career path more than they know.   
v 
 
Table of Contents 
Abstract .......................................................................................................................................... ii 
Acknowledgments ........................................................................................................................ iv 
List of tables................................................................................................................................. vii 
List of figures .............................................................................................................................. viii 
Background ................................................................................................................................... 1 
Measuring population immunity ........................................................................................................... 1 
Potential uses for serological surveys .................................................................................................... 4 
The case for measles and rubella seroepidemiology ............................................................................ 6 
Measles and rubella serosurveys ........................................................................................................... 9 
Design and implementation of serosurveys ........................................................................................ 11 
Method of specimen collection .......................................................................................................... 12 
Acceptability of serosurvey participation ........................................................................................... 13 
Costs associated with serological surveys .......................................................................................... 16 
Measles and Rubella in Zambia .......................................................................................................... 20 
Parent study: Strengthening Immunization Systems through Surveillance (SISS) ....................... 25 
First serosurvey: ZamPHIA ............................................................................................................... 26 
Second serosurvey: nested within PCES ............................................................................................ 27 
Introduction to dissertation ....................................................................................................... 28 
Specific aims .......................................................................................................................................... 28 
Data sources .......................................................................................................................................... 29 
Ethical approvals .................................................................................................................................. 31 
Paper 1- Acceptability of a serosurvey for vaccine preventable diseases in rural southern 
Zambia: surveyor and community perspectives ...................................................................... 32 
Abstract ................................................................................................................................................. 32 
Background ........................................................................................................................................... 34 
Methods ................................................................................................................................................. 35 
Results .................................................................................................................................................... 39 
Discussion .............................................................................................................................................. 54 
Conclusion ............................................................................................................................................. 59 
Tables and Figures................................................................................................................................ 60 
Paper 2- How much does it cost to measure immunity? A costing analysis of a measles and 
rubella serosurvey in Zambia .................................................................................................... 65 
Abstract ................................................................................................................................................. 65 
Introduction .......................................................................................................................................... 67 
Methods ................................................................................................................................................. 69 
Results .................................................................................................................................................... 73 
Discussion .............................................................................................................................................. 76 
Conclusion ............................................................................................................................................. 81 
Tables and Figures................................................................................................................................ 82 
Paper 3- Comparing two serosurveys in Southern Province, Zambia to assess the impact of 
a measles and rubella vaccination campaign on seroprevalence ............................................ 90 
Abstract ................................................................................................................................................. 90 
Introduction .......................................................................................................................................... 92 
Methods ................................................................................................................................................. 94 
vi 
 
Results .................................................................................................................................................. 100 
Discussion ............................................................................................................................................ 104 
Conclusion ........................................................................................................................................... 110 
Tables and Figures.............................................................................................................................. 112 
Discussion................................................................................................................................... 126 
Public Health Importance .................................................................................................................. 126 
Limitations .......................................................................................................................................... 131 
Next Steps and Recommendation for Future Research .................................................................. 133 
Conclusion ........................................................................................................................................... 136 
Appendices ................................................................................................................................. 137 
Appendix 1. Glossary of terms .......................................................................................................... 137 
Appendix 2. Interview and focus group guides from Paper 1 ........................................................ 138 
Appendix 3. Post-introduction evaluation caregiver questionnaire for Paper 1 .......................... 147 
Appendix 4. Post-campaign serosurvey data collection questionnaire .......................................... 150 
Appendix 5. Quality control procedures for pre-campaign serosurvey laboratory testing ......... 152 
Appendix 6. Pre-campaign measles serosurvey laboratory testing with alternate cut-off value . 154 
REFERENCES .......................................................................................................................... 156 





List of tables 
Table 1. Potential uses for serological surveillance (Adapted from (Cutts & Hanson, 2016)) ...... 5 
Table 2. Socio-ecological Model (adapted from (McLeroy et al., 1988)) .................................... 16 
Table 3. Cases of measles and rubella in Zambia reported to WHO, 2010-2016* ....................... 22 
Table 4. Data sources used for each paper .................................................................................... 30 
Table 5. Characteristics of data collectors who participated in in-depth interviews and focus 
group discussions .......................................................................................................................... 60 
Table 6. Sociodemographic factors and serosurvey response characteristics of caregivers who 
participated in the survey .............................................................................................................. 60 
Table 7. Caregiver barriers and facilitators to serosurvey participation (n=34)* ......................... 62 
Table 8. Reasons for preferring a specimen type (n=34) .............................................................. 63 
Table 9. Costs per phase of serosurvey implementation in Southern province, Zambia .............. 82 
Table 10. Sample size costing with varying precision by changing the number of clusters ........ 82 
Table 11. Sample size costing with varying precision by changing the number of participants per 
cluster ............................................................................................................................................ 83 
Table 12. Comparisons between pre and post-campaign serosurvey design .............................. 112 
Table 13. Study population characteristics in pre and post-campaign serosurveys, weighted ... 115 
Table 14. Provincial level seroprevalence estimates to measles and rubella pre and post-
vaccination campaign—unweighted, weighted, and direct adjustments .................................... 116 
   
viii 
 
List of figures 
Figure 1. Measles cases and immunization campaigns in Zambia ............................................... 21 
Figure 2. SISS intersection of country priorities and operational research objectives ................. 25 
Figure 3. Selected enumeration areas included in ZamPHIA study ............................................. 26 
Figure 4. Selected enumeration areas included in the post-campaign vaccination coverage survey
....................................................................................................................................................... 27 
Figure 5. Emerging themes related to acceptability of a serosurvey within a socioecological 
model............................................................................................................................................. 63 
Figure 6. Pairwise specimen preference among caregivers comparing oral swab, venous blood 
and finger prick collection methods .............................................................................................. 64 
Figure 7. Framework for estimating serosurvey costs .................................................................. 84 
Figure 8. Costs for the post-campaign vaccine coverage survey and serosurvey in Southern 
Province, Zambia by input category ............................................................................................. 85 
Figure 9. One-way sensitivity analyses of costs varying serosurvey parameters ......................... 86 
Figure 10. Sample size costing with varying estimates of seroprevalence at +/-5% precision .... 87 
Figure 11. Sample size costing with varying precision at 85% seroprevalence with design effects 
of 1.4 and 2.0 ................................................................................................................................ 88 
Figure 12. Sample size options for setting with 85% population immunity and +/-5% precision 89 
Figure 13. Model of factors associated with being included in the serological surveys, which 
affect seroprevalence estimates ................................................................................................... 117 
Figure 14. Relationship of seropositivity and age in the pre and post-campaign serosurveys, 
polynomial regression spline ...................................................................................................... 118 
Figure 15. Seroprevalence estimates to measles and rubella by age categories pre and post 
measles-rubella vaccination campaign—weighted ..................................................................... 120 
Figure 16. Seroprevalence estimates to measles by age categories and sex pre and post measles-
rubella vaccination campaign—weighted ................................................................................... 121 
Figure 17. Seroprevalence estimates to rubella by age categories and sex pre and post measles-
rubella vaccination campaign—weighted ................................................................................... 122 
Figure 18. Kernel density plot of IgG antibody concentrations pre and post measles-rubella 
vaccination campaign for participants by under 15-year olds and 15 years of age and older .... 123 
Figure 19. Measles and rubella seroprevalence estimates among HIV infected and uninfected 





In 2012, the Global Strategic Plan for Measles and Rubella established goals of reaching 
elimination of measles in at least five World Health Organization (WHO) regions and rubella in 
three regions by 2020. The Region of the Americas is the only region thus far to achieve the 
elimination of rubella in 2015 (Pan American Health Organization, 2016).  While elimination of 
measles was reached in the Americas in 2016, this status was lost in 2018 due to re-established 
transmission in Venezuela, highlighting the fragility of measles elimination status (Pan American 
Health Organization, 2018). The strategy for elimination includes high vaccination coverage, 
laboratory surveillance, monitoring and evaluation, outbreak response, and community 
engagement. In order to design the elimination program, countries should set target levels of 
immunity, establish current immunity profiles, and identify strategies to increase immunity to 
reach the target.  Serological surveillance can help to establish immunity profiles and identify 
population immunity gaps, which can be targeted for vaccination to ensure herd immunity 
thresholds are met so virus transmission can be interrupted (Trentini, Poletti, Merler, & 
Melegaro, 2017). 
Measuring population immunity 
Population immunity is the percentage of people in a given area protected against a 
disease. There are primarily three data sources ued to estimate population immunity: vaccination 
coverage, surveillance, and serological surveillance. 
Population immunity profiles are often inferred from vaccination coverage data; 
however, these data can be of poor quality. Vaccination programs in low and middle-income 
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countries estimate vaccination coverage through: (1) immunization registries and routine 
administrative reporting; and (2) household surveys (Travassos et al., 2015). The best estimates 
of vaccination coverage for low and middle-income countries come from the WHO and United 
Nations Children’s Fund (UNICEF) immunization coverage estimates which incorporate both 
administrative and survey data to establish one estimate per country on an annual basis. 
However, there are several data quality issues with routine administrative reporting.  
Administrative vaccination coverage has been reported over 100% in some districts, and has 
been found to not match survey data (MacNeil, Lee, & Dietz, 2014). Biased reporting can also 
occur during routine administrative reporting due to duplications of vaccination records, not 
accounting for private providers, and administrative or organizational changes such as 
redistricting. Additionally, immunization registries measure only the numerator, which is the 
number of children who have been vaccinated and could potentially count the same child 
vaccinated twice as different children. Immunization registries also do not account for 
denominator issues such as incomplete birth registration or migration.  
 Given the issues with routine administrative data, WHO and UNICEF incorporate survey 
data into their estimates of vaccination coverage. Two large multi-purpose surveys that are 
conducted on a routine basis are the Demographic Health Survey (DHS), supported by the 
United States Agency for International Development, and the Multiple Indicator Cluster Survey 
(MICS) supported by UNICEF. Both surveys are multi-stage cluster surveys with standardized 
questionnaires and field workers who collect data. Validation studies have suggested that DHS 
and MICS survey instruments had 44% sensitivity and 38-49% specificity for measuring measles 
containing vaccine (MCV) coverage (Liu et al., 2013). The main potential sources of error in 
population-based surveys measuring vaccination coverage include: sampling error; selection bias 
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due sampling issues; information bias due to poor field procedures, home-based records and 
inaccurate verbal history; and data entry or missing data (Cutts, Izurieta, & Rhoda, 2013). Other 
disadvantages of these surveys are that they are costly, require up to a year of planning, and are 
not generally designed to measure district-level coverage.  
Neither routine administrative data nor household surveys directly measures population 
immunity. Because vaccination coverage is only a proxy measure for population immunity, it 
can be biased. In the absence of wild-type virus circulation, population immunity will generally 
be lower than vaccination coverage, as only “effective” vaccinations, which induce immunity in 
recipients, will be measured (Colson, Zuniga-Brenes, et al., 2015; Ibrahim, Abdallah, Saleh, 
Osterhaus, & De Swart, 2006).  If multiple doses are offered, the second dose may be 
disproportionately given to individuals who already have a first dose of vaccine, thus not 
necessarily improving population immunity (Lessler et al., 2011). If there is a large outbreak of 
measles or rubella, population immunity would be expected to be higher than reported 
vaccination coverage due to naturally acquired immunity in addition to immunity from 
vaccination. Under reporting of coverage, potentially due to vaccines provided in the private 
sector, could suggest lower than true population immunity. In contrast, over reporting of 
vaccination coverage would provide a biased population immunity estimate that is higher than 
true immunity (Thompson, Odahowski, Goodson, Reef, & Perry, 2016). If a vaccine has a low 
seroconversion rate, vaccine immunogenicity is interfered by maternal immunity, or the vaccine 
loses potency from poor transportation or storage, the vaccination would not be effective, so 
serology would underestimate the proportion of children vaccinated.  
A second option for inferring population immunity is to use disease surveillance data, 
which identifies immunity gaps in those who become diseased. Surveillance data for measles is 
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immediately notifiable and laboratory-verified; however the quality of this data can vary. 
Furthermore, surveillance systems suffer from selection bias. Only cases who present to the 
health system would be included, so there is often under reporting of cases (Plans-Rubio, 2014). 
Additionally, verification of cases is often done at the national level, so ensuring cases are 
reported from all geographic regions can be challenging for specimen transport. The age-
distribution of cases allows for the identification of immunity gaps by age group. This often 
works best when there is a large outbreak of disease, covering a wide age range, so there is 
sufficient data to create an age-specific immunity profile. This could identify age-specific 
immunity gaps that existed before the outbreak and provide a sense of who was susceptible at the 
start of the outbreak. Deriving population immunity from surveillance systems can be 
challenging and could misrepresent immunity gaps. 
Population immunity can be directly measured through seroepidemiology (Winter et al., 
2018).  Seroepidemiology can be defined as “the collection and use of data on the prevalence of 
antibodies in serum or related fluids to study the distribution and determinants of infection” 
(Cutts & Hanson, 2016). Monitoring the prevalence of these antibodies can be a powerful tool to 
design and monitor vaccination programs to maintain high population immunity; however, they 
are not often used because they are expensive and logistically challenging. 
Potential uses for serological surveys 
In order for a disease to be a strong candidate for seroepidemiology, there must be a good 
serological marker of protection, a valid test for measuring the antibody, and it must be a priority 
for the immunization program. Seroepidemiology can be used to measure population immunity 
in three different instances: prior to vaccine introduction, once a vaccine has been introduced 
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into routine immunization, and to assess the impact of a vaccination campaign. Within these 
broad scenarios, serological surveillance can have several different uses, though each would 
require different characteristics for each pathogen (Table 1). This could help not only assess 
where current population gaps are but how to target vaccination efforts to improve immunity 
levels (Trentini et al., 2017). Based on the granularity of available data, serosurveys could guide 
the age range or geographic areas where vaccination may be needed (Lessler, Metcalf, Cutts, & 
Grenfell, 2016). 
 
Table 1. Potential uses for serological surveillance (Adapted from (Cutts & Hanson, 2016))  
Potential use Required characteristics 
Assess vaccination coverage • No natural infection or testing can distinguish 
antibody induced by vaccine from that by 
infection 
• Predictable immunogenicity 
• Antibody of known duration 
• Antibody levels correlate with number of doses of 
vaccine received 
Estimate burden of disease • Antigen or antibody correlates with infection 
Select groups to target 
vaccination 
• Protective antibody follows infection and is stable 
over time, so that seroprevalence by age signals 
age-specific or geographic immunity gaps 
Determine elimination 
thresholds 
• Protective antibody follows infection and is stable 
over time 
Understand waning immunity • Antibody is main correlate of protection 
Predict risk of outbreaks • Antibody is main correlate of protection 
• Protective antibody level is established 




The case for measles and rubella seroepidemiology 
Measles is a highly infectious disease that was estimated to result in two million deaths 
worldwide each year before the availability of vaccine (Moss, 2012). For every case of measles, 
there are an estimated 12-18 secondary cases in a completely susceptible population. This is 
defined as the basic reproductive number, which determines the herd immunity threshold, and 
therefore vaccination coverage required to achieve herd immunity (Guerra et al., 2017). Measles 
vaccine began being used in the 1960s, and measles vaccine was included in the original 
Expanded Program on Immunization (EPI) which started in 1974 (Bland & Clements, 1998). In 
2000, measles deaths accounted for 5% of under-five mortality (UNICEF, 2011). Following an 
increase in coverage with two doses of measles vaccine, estimated measles deaths dropped by 
80% from 545,174 in 2000 to 109,638 in 2017 worldwide, with Africa accounting for 44% of 
measles deaths (Dabbagh et al., 2018).  
 Measles is a good candidate for serological surveillance because it induces a lasting 
antibody response and has established cutoffs indicating protective immunity. The correlate of 
protection for measles are reported to be measles-specificIgG antibody levels of >120 mIU/ml 
following vaccination when measured by plaque reduction neutralization assay (Chen, 1990).  
IgG levels are highest approximately 2 weeks after rash onset and are detectable for life 
(Gastanaduy, 2013). Laboratory testing for measles IgG is relatively straightforward and there 
are commercially available ELISA kits for blood and oral fluid samples which are relatively 
rapid and easy to use in the laboratory setting (World Health Organization, 2019). However, 
measles antibody detection cannot distinguish between natural infection and vaccine-induced 
immunity. Therefore, in a setting with circulating wild-type measles virus, serological 
surveillance would not be a good indicator of vaccination coverage, although it is still an 
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effective measurement of population immunity. This would more accurately identify the 
proportion of people susceptible than using vaccination coverage and measles case-based 
surveillance alone because it accounts for both natural immunity as well as vaccine induced 
immunity. Serological surveillance is currently being used in many European countries, the 
United States, Canada, and Australia and has been used for vaccine policy decision making 
(Nardone et al., 2008; Wilson, Deeks, Hatchette, & Crowcroft, 2012). Ten years of serological 
surveillance in the United Kingdom provided data on the susceptible population to be targeted 
for a national measles-rubella (MR) campaign in 1994, and the information for justifying the 
need for a second dose of measles-mumps-rubella (MMR) vaccine at 4 years of age (Osborne, 
Gay, Hesketh, Morgan-Capner, & Miller, 2000). Similarly, Canada’s serological surveillance 
provided evidence for the introduction and timing of a second dose of measles-mumps-rubella 
vaccine to improve population level immunity (Ratnam, West, Gadag, Williams, & Oates, 1997). 
Like measles, rubella is transmitted by the respiratory route. It is generally a mild disease 
in children but can cause severe sequelae in pregnant women, resulting in miscarriage or 
congenital rubella syndrome (CRS) in the fetus, a combination of conditions which include heart 
disease, blindness and deafness. For every case of rubella, there are an estimated 5-7 secondary 
cases in a completely susceptible population. Rubella vaccine began being used in 1969, and 
combination MR and MMR in the 1970s (World Health Organization, 2012). WHO published 
the first rubella vaccine position paper to guide countries in introducing rubella containing 
vaccine in 2000. The number of countries using rubella vaccine increased from 83 in 1996 to 130 
in 2009 (Reef, Strebel, Dabbagh, Gacic-Dobo, & Cochi, 2011). Although not a major cause of 
childhood mortality, rubella is a major cause of congenital defects, estimated to affect 105,391 
infants in 2010, with 37% of cases in Africa (Vynnycky et al., 2016).  
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Rubella is also a strong candidate for serological surveillance because rubella-specific 
IgG antibodies are a good serological marker of immunity, there is a valid test for measuring 
antibodies, and both infection and immunization result in lifelong immunity. The correlate of 
protection cutoff for IgG antibodies to rubella virus was established at 10–15 mIU/ml. (Plotkin, 
2010). The limitation is that antibody detection cannot distinguish between natural immunity and 
vaccine-induced immunity. Serological surveillance provides more accurate data than disease 
surveillance reports because rubella is an under-notified disease due to the fact that rubella virus 
infection is subclinical in up to 50% of cases (Lanieri T, 2008). Even when there is no report of 
rubella cases, serological surveillance can provide evidence of circulating virus in the absence of 
vaccination (Clarke, Schild, Boustred, McGregor, & Williams, 1980). Therefore, serological 
surveillance is an important supplement to traditional case-based surveillance. The presence of 
IgG antibodies in serum can be used to indicate the immune status of a person whose history of 
rubella disease or vaccination is not known. 
Given that both measles and rubella provide long-lasting immunity through vaccination 
or natural infection, including both in a serological survey is feasible. It is also efficient, as with 
sufficient volume, the same specimen can be used to test for antibodies to both measles and 
rubella viruses. Furthermore, including both measles and rubella together in a serosurvey is 
logical given their link in public health programs. The surveillance system for fever and rash 
illness captures cases of both, and laboratory testing is recommended for both pathogens to be 
done simultaneously (World Health Organization, 2019). Additionally, the combination measles-
rubella vaccine being rolled out in many countries, may mean children susceptible to measles are 
also susceptible to rubella if they have not been vaccinated against either (Libman, Behr, Martel, 
& Ward, 2000). 
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Measles and rubella serosurveys 
 Measles and rubella serosurveys have been conducted for decades. One systematic 
review identified 477 measles and rubella serology studies through June 2014, mostly focused in 
developed countries (Thompson & Odahowski, 2016). The authors highlight the increased 
demand for serosurveys as burden of disease decreases to identify pockets of risk as countries 
move towards elimination. A recent review by the WHO Measles and Rubella Laboratory 
Network assessed 16 years of serological surveys, 68 for measles and 58 for rubella (Dimech & 
Mulders, 2016a). Of the 36 countries that conducted serological surveys, only 13 measles and 8 
rubella serosurveys were conducted in developing countries, only five of which were in Africa. 
Most serosurveys were conducted for monitoring susceptibility through antibody detection as a 
cross-sectional survey (68%), though others were used to measure antibody persistence, estimate 
vaccination coverage and calculate vaccine immunogenicity. The study age ranges included 
infants, children, adolescents, adults, women of childbearing age. Study sizes varied from 70 to 
over 412,000, with around 30% of studies having over 2,000 individuals. The seroprevalence in 
these studies ranged from 60.8-95.9% for measles and 53.0-99.3% for rubella.  
These serological studies varied in their methodologies and objectives. The specimen 
type ranged from serum to plasma and oral fluid to breast milk. Furthermore, some studies used 
enzyme immunoassays, while others used neutralization assays, automated immunoassays, 
hemagglutination inhibition assays and bioplex assays. In addition, these studies used a range of 
different quantitative cutoff values to classify seropositive results. The authors conclude that the 
results of different rubella and measles EIAs are not comparable despite being calibrated against 
WHO international standards. They also highlight the variability in tests and testing strategies 
and the implications that could have on seroprevalence. They recommend using only 
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serum/plasma specimens as a way of standardizing test results across serosurveys. Furthermore, 
they suggest calibrating the ELISA against plaque reduction neutralization tests (PRNT) using 
WHO international standards as another means to standardize testing between serosurveys, as 
PRNT has better sensitivity and was used to demonstrate correlation of protection for measles 
(Dimech & Mulders, 2016b). 
 A 2015 systematic review specific to rubella serology in African countries found that 
immunity ranged from 52.9 to 97.9%. Immunity among pregnant women ranged from 52.9% to 
97.9% (Mirambo, Majigo, Aboud, Gross, & Mshana, 2015). Few studies compared rural and 
urban settings, but these did not find statistically significant differences (Amina et al., 2010; 
Barreto et al., 2006; Mwambe et al., 2014; Tahita et al., 2013). Almost all the studies were 
conducted among adults over the age of 15 years, and few studies provided any information on 
immunity by age groups (Amina et al., 2010; Kolawole, Anjorin, Adekanle, Kolawole, & 
Durowade, 2014; Kombich JJ, 2012; Mwambe et al., 2014; Onakewhor & Chiwuzie, 2011; 
Tahita et al., 2013). The authors also noted that seasonality in transmission was not included in 
any of the articles and that there is much information still missing to accurately characterize 
rubella dynamics in Africa (Mirambo et al., 2015). 
Serosurvey guidelines have been developed to provide guidance for planning and 
implementing serosurveys for measles and rubella. The target audience is immunization program 
managers, epidemiologists and laboratorians working on measles and rubella elimination efforts. 
It outlines potential key stakeholders; survey planning and protocol development including 
design and methods; budget and timeline; ethical considerations; survey implementation such as 
sampling procedures, training and supervision of field and laboratory teams, data collection and 
management; laboratory methods including specimen transport and processing, choice of 
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specimen, serological assays and quality of control; and data analysis. As more countries 
introduce rubella containing vaccine and near measles and rubella elimination, serological 
surveys can serve as additional criteria to monitor the needed population immunity threshold for 
the certification of elimination.  
Design and implementation of serosurveys 
To plan for and implement serological surveys, there are several considerations to be 
made, as serological surveys are not appropriate to answer all public health research questions. 
The objectives and expected outcomes of the serosurvey need to be clearly outlined to guide the 
study design. Major methodological considerations to be considered include population sampling 
methods, selection of specimens to be collected, laboratory assays, and cost implications. 
 In terms of population sampling methods, serological surveys can use either previously 
collected specimens from biobanks for testing or prospectively collect new specimens. In both 
instances, samples can be acquired from convenience samples. Such convenience samples may 
include specimens collected for fever and rash illness surveillance, antenatal care specimens, 
human immunodeficiency virus (HIV) serological surveys, malaria indicator surveys, and other 
vaccine preventable disease (VPD) monitoring, such as Hepatitis B or Tetanus. It could also 
include samples collected in routine multi-purpose surveys such as DHS and MICS. Using 
convenience samples is logistically easier and can be cheaper due to the reduced cost of 
specimen collection but provides little control over sampling error and bias.  
Prospective specimen collection allows for better control of data collection and sampling 
methodologies but can be costly and logistically challenging (Metcalf et al., 2016). Individual 
surveys for a specific antigen can be collected either as part of another activity, such as post-
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vaccination coverage survey, or as a stand-alone serological survey for that specific antigen, and 
there are tradeoffs involved with doing each of these methodologies. Vaccination coverage 
surveys are often conducted at the household and could be combined with specimen collection to 
reduce fieldwork costs (Cutts et al., 2013). The WHO EPI cluster survey measures vaccination 
coverage based on caregiver recall and vaccination card but does not include biological specimen 
collection. Adding this component to vaccination coverage survey has been successfully done in 
low-income settings (Travassos et al., 2015). Advocates for collecting biospecimens as part of 
immunization coverage surveys have noted that there may be issues with logistical feasibility, 
cost implications and survey implementation (MacNeil et al., 2014). Other concerns are that the 
main survey may not have the same target population or sampling plan sufficient to meet the 
objectives of the serosurvey, and specimen collection might compromise the acceptability of the 
main survey (World Health Organization, 2015). 
Method of specimen collection 
There are different specimen types that can be used for serosurveys depending on the 
antigen and antibody class of interest: serum, dried blood spot, oral fluid, and breast milk. Serum 
and dried blood spots (DBS) are the most commonly used specimen types in serological 
surveillance and most commercially available measles and rubella assays are validated for 
serum. The concentration of antibodies in other sample types is generally lower than serum, 
which could decrease the sensitivity of the laboratory assay (World Health Organization, 2015). 
However, serum samples must be kept at cold temperatures, and specimens must arrive at the 
laboratory within 48 hours of collection, which can be logistically challenging. Therefore, an 
alternative is to place small volumes of dried blood on filter paper, as antibodies remain stable at 
room temperature for several days (Punnarugsa & Mungmee, 1991). Challenges with DBS are 
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that the eluted volume may be insufficient and require additional steps in the laboratory to elute 
and process specimens (Snijdewind et al., 2012). Concordance between serum and dried blood 
spots has been found to be as high as 92-93% for both measles and rubella IgG (Colson, Potter, 
et al., 2015; Helfand et al., 2001). 
Dried blood spots from finger prick have been suggested for use in measles serological 
testing since as early as 1994 as an alternative specimen collection method that can provide 
similar serological results as serum (Parker & Cubitt, 1999). Finger pricks are a minimally 
invasive way to collect dried blood spots and can be collected through single-use lancet devices 
which minimize pain and bruising (Mei, Alexander, Adam, & Hannon, 2001). Finger pricks also 
have the added advantage of not requiring a phlebotomist or specialized healthcare professional, 
but rather can be performed by trained community health workers (Harvey et al., 2008; Novello 
et al., 1996). Additionally, finger pricks tend to require less time and have a lower risk for 
participants (World Health Organization, 2010). 
Acceptability of serosurvey participation 
Recruitment and retention of a representative population is crucial to the validity of 
research studies, including serosurveys (Durrheim, Orenstein, & Schluter, 2018). However, the 
factors associated with whether individuals choose to participate in a serosurvey are not well 
understood.  The issue of selecting which specimen type to collect is tied to both laboratory 
assay selection as well as acceptability of specimen collection methodology. If people are more 
likely to accept finger prick than a vein puncture, this could change participation rates in the 
serosurvey. Collecting a biological sample could decrease response rates in a survey, and if more 
people refuse to provide a specimen, this could compromise the generalizability of the survey 
results (MacNeil et al., 2014).   
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The decision to participate in serosurvey research is affected by a balance of motivators 
and deterrents to participation (Almeida, Azevedo, Nunes, Vaz-da-Silva, & Soares-da-Silva, 
2007). Motivating reasons for participation can include direct individual benefits such as 
financial incentives or perceived direct protection from disease (Dhalla & Poole, 2014). 
Perceived disadvantages for participating in a serosurvey include exposure to risks associated 
with taking blood samples, such as pain and crying among children. There are also concerns with 
the use of specimens for reasons other than those detailed in the study as well as not receiving 
results from the tests conducted (Chatio, Baiden, Achana, Oduro, & Akazili, 2016).  However, 
beyond direct benefits, other reasons healthy individuals participate in research include altruistic 
reasons, community benefits, a desire to assist with overall disease reduction, and a feeling of 
accomplishment by contributing to research (Dhalla & Poole, 2014). Understanding the social 
benefits that motivate research participants provide an additional perspective to the direct 
personal benefits (Nyaoke et al., 2017). This belief in the societal benefits of research may be 
key to serosurvey participation, as serosurveys may not directly benefit the individual who is 
providing the blood specimen if they will not be given their test results.  
Participants often consult other people, such as family, friends, or healthcare workers, 
before agreeing to take part in research; therefore, the decision making process is not just at the 
individual level (Almeida et al., 2007).  Conceptual models, such as the socio-ecological model, 
have been used to identify different spheres of influence, like community-level influences, on 
research participation (Salihu, Wilson, King, Marty, & Whiteman, 2015).  The socio-ecological 
model posits that people’s behavior is determined not just by individual-level aspects but also by 
intrapersonal factors, interpersonal processes, institutional factors, community factors, and public 
policy (McLeroy, Bibeau, Steckler, & Glanz, 1988). Table 2 defines these levels and how they 
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could apply in the context of serosurveys. This interplay of factors can affect whether people 
participate in research, including the influence of social norms and community leaders (Nyaoke 
et al., 2017). The engagement of community and religious leaders through social mobilization 
has been recognized as an important component of community acceptance of survey 
participation. Additionally, using local health workers who are already known to the community 
to accompany teams and answer questions can help improve acceptability (Travassos et al., 
2015).  
Serosurveys may require additional resources for social mobilization because they collect 
biological specimens, often blood, from participants (Bryant Borders, Grobman, Amsden, 
Collins, & Holl, 2007). Refusal rates may be higher for surveys that collect blood specimens than 
surveys that collect only questionnaire data due to potential discomfort, added time for specimen 
collection, or participants not trusting what is being done with their blood (MacNeil et al., 2014). 
To monitor how non-participation could introduce bias, refusal rates for serosurvey participation 
are tracked and reported, as those who participate may be different than those who refuse. 
However, there are limited data explaining why individuals refuse to participate in serosurveys in 
sub-Saharan Africa (Travassos et al., 2015). Understanding the reasons behind acceptability of 





Table 2. Socio-ecological Model (adapted from (McLeroy et al., 1988)) 
Concept Definition Potential applications to 
serosurveys 
Intrapersonal factors Characteristics of the 
individual, such as 
knowledge, attitudes, 
behavior, self-concept  
 Knowledge about 
serosurveys (ex. blood 
collection, laboratory 
tests), attitudes towards 
participating in 
serosurveys 
Interpersonal factors  Formal and informal social 
network and social support 
systems, including family, 
friendships 
Family, community 
members opinions about 
participating in 






characteristics, and rules 
and regulations for 
operation 
Institution/organization 
carrying out the 
serosurvey, and logistics 
of how serosurvey is 
being implemented 
Community factors Relationships among 
organizations, institutions 
and informal networks 










Costs associated with serological surveys 
WHO estimates that a serosurvey could cost anywhere from $100,000 to over $1 million 
to implement (Patel, 2016). While much of this variability may be due to the design of the 
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serosurvey, understanding what the drives the costs of serosurveys beyond the required tools for 
specimen collection and laboratory processing is not well defined. 
 Some of the costs of serosurveys are costs that would be required for any survey, 
regardless of whether they include biospecimen collection or not, such as vaccination coverage 
surveys or DHS. These include data collection costs such as travel and fieldwork including 
participant enrollment and questionnaire administration (Luman, Worku, Berhane, Martin, & 
Cairns, 2007).  
Another  major driver of cost is the sample size of a survey, which is influenced by the 
prevalence of what is being estimated (Turner, Magnani, & Shuaib, 1996). Sampling strategies 
contribute to the cost of surveys differently, and understanding the implications of sampling on 
serosurveys could help determine their feasibility (Parker & Cubitt, 1999). Examining how much 
it costs to include an additional household versus an additional cluster in a serological survey 
could have implications on how decision makers’ budget for serological surveys. Some 
serological surveys may choose to collect questionnaire data from a larger study population and 
collect biological specimens from a smaller subset of the study population. Understanding how 
different sampling strategies may contribute to the cost of serological surveys would help 
determine the feasibility of serological surveys. 
Another potential means of reducing cost would be to refer participants to a health 
facility for blood collection rather than collecting blood in the community setting. However, 
requiring participants to reach the health care facility in order to participate can lead to selection 
bias, as this may introduce barriers for participants who would otherwise be willing to enroll. 
Collecting biological specimens at the households may overcome logistical barriers and increase 
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participation. However, collecting, processing and transporting blood specimens in the field can 
be expensive and logistically challenging to accomplish (Bryant Borders et al., 2007).   
One of the reasons serosurveys can be costly is that biological specimen collection 
requires trained skilled workers or healthcare professionals for implementation. Additionally, 
biological specimens have an added cost of specimen collection supplies, storage and transport, 
laboratory testing, and additional human resources for laboratory processing (MacNeil et al., 
2014). It is estimated that 60-70% of a serosurvey budget is laboratory-related supplies for blood 
collection, storage, transport, processing, and testing kits (World Health Organization, 2015). 
Collection and processing of DBS is thought to be cheaper than samples collected by 
venipuncture due to reduced costs of specimen collection and transport, though it requires an 
additional laboratory processing step which could offset the cost-savings in the field (Parker & 
Cubitt, 1999). Another way to reduce costs in the field would be to use already collected 
specimens, which could eliminate the costs of specimen collection. 
 While there have been concerns voiced about the cost of serosurveys, actual cost 
estimates are scarce. Most costing studies for measles and rubella have primarily focused on the 
cost-effectiveness of vaccine programs (Babigumira, Morgan, & Levin, 2013; Coppeta, Morucci, 
Pietroiusti, & Magrini, 2019). Pre-vaccination cost studies have assessed the costs of screening 
healthcare workers as well as antenatal screening of pregnant women (Ferson, Robertson, & 
Whybin, 1994; Lugner, Mollema, Ruijs, & Hahne, 2010). There have also been cost analyses of 
surveillance systems for vaccine preventable diseases (Duintjer Tebbens, Diop, Pallansch, 
Oberste, & Thompson, 2019; Erondu, Ferland, Haile, & Abimbola, 2019). A methodology was 
developed to cost integrated vaccine-preventable disease surveillance systems that includes 
calculating personnel costs and laboratory costs (Toscano et al., 2013). 
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 A comparison of vaccination coverage survey methodologies demonstrated that there was 
no difference in cost between conducting an EPI cluster survey and a systematic random 
sampling survey (Luman et al., 2007). Although the average time to survey a cluster, household 
and child differed between the two sampling methods; the total time to complete the first 30 
households remained the same. Costing for time was broken down into time for travel, searching 
for a household to enroll, and interview. Another comparison between the EPI cluster survey 
methodology with probabilistic cluster survey methods noted that probabilistic methods provide 
a more statistically robust measurement with probability of selection for each cluster, household 
and child (Turner et al., 1996). However, because this methodology requires household listing of 




Measles and Rubella in Zambia 
 Zambia is a low-income country in Southern Africa with a population of approximately 
16 million and an annual birth cohort of 645,000 (GAVI, 2018). The country is divided into 10 
provinces and 72 districts, with 41% of the population living in urban areas. Under-five mortality 
declined from 191 per 1,000 live births in 1990 to 64 per 1,000 in 2015, and is ranked 25th in the 
world (UNICEF, 2013). According to WHO estimated, the major causes of under-five mortality 
in Zambia in 2016 included neonatal disorders (33%), lower respiratory infections (14%), HIV 
(9%), diarrheal diseases (7%), and malaria and malnutrition (7%). Measles accounted for less 
than 1% of under-five deaths according to 2016 estimates (World Health Organization, 2018a). 
 Although the burden of measles in Zambia has been decreasing, it remains a periodic 
cause of mortality and morbidity (Figure 1).  Prior to measles vaccine introduction in 1983, the 
disease affected mostly children. The first dose of measles vaccine is given at 9 months of age. 
Reported vaccination coverage increased from 74% in 1999 to 95% in 2005 (Centers for Disease 
Control and Prevention, 2005). From 2005-2016, WUENIC estimates of vaccination coverage 
ranged from 80-96%, which are generally lower than reported administrative coverage during 
this time (UNICEF, 2017). A second dose of measles vaccine was added to the EPI schedule in 
July 2013, and coverage climbed to 65% in 2018. In addition to routine measles vaccine, there 
have been periodic supplementary immunization activities conducted approximately every 2-4 
years to address immunity gpas in children who may have missed routine immunization. These 
have ranged from being only a few districts to being nationwide campaigns, generally targeting 
9-59-month olds or 9 month-14-year olds. These campaigns should have helped bolster 




Figure 1. Measles cases and immunization campaigns in Zambia 
 
 Measles and rubella cases are captured through the fever and rash illness surveillance 
system in Zambia. All suspected cases are intended to be tested for measles and rubella IgM 
antibodies. Confirmed cases are those with positive laboratory testing, epidemiologically linked 
do not have laboratory confirmation but are linked to a confirmed case, and clinical cases are 
those that present clinically but may not have laboratory test confirmation. To assess the quality 
of the fever and rash illness surveillance system, several indicators are the surveillance system 
are routinely measured.  The primary measles surveillance indicators are: (1) to meet a non-
measles febrile rash illness rate of at least 2 per 100,000 population; and (2) to have at least 80% 
of districts report at least 1 suspected case of measles with a blood specimen per year. In 2012, 
Zambia met the first target; in 2013, it met neither of these targets; and in 2016, it met only the 
second (Masresha et al., 2017; Masresha et al., 2014). Although the surveillance system is 




Table 3. Cases of measles and rubella in Zambia reported to WHO, 2010-2016*  
 2010 2011 2012 2013 2014 2015 2016  2017 2018 
MEASLES 15,754 13,234 896 35 9 9 8 13 11 




0 0 0 0 10 3 0 0 - 
 
Currently there are no national goals for measles, rubella or CRS control or elimination in 
Zambia, although there is a WHO AFRO regional measles elimination goal by 2020. Rubella is 
not a reportable disease in Zambia and is therefore primarily detected through laboratory testing 
of suspected fever and rash cases. According to the surveillance system, peaks of rubella 
occurred in 2004, 2005, 2008 and 2009, when measles positivity was low. There was a large 
outbreak in 2011, which occurred simultaneously with a large measles outbreak. Rubella appears 
to have a seasonal pattern in Zambia, with most cases occurring between August and December. 
It was estimated that children ages 5-14 years represented most rubella infections (M. Mazaba et 
al., 2012). Zambia does not have sentinel surveillance for monitoring CRS. In 2012-13, case 
reports documented the first laboratory-confirmed CRS cases in Zambia, all from the same 
hospital, though these are not counted in the WHO reports of CRS (M. L. Mazaba et al., 2014). 
One mathematical model predicted the incidence of CRS to be 123 per 100,000 live births (95% 
confidence interval 29-246) (Cutts & Vynnycky, 1999). Given that the yearly birth cohort is 
estimated at 644,972, the number of CRS cases would be expected to be much higher than the 
reported number of 10 in 2014, indicating an underreporting of CRS cases (GAVI, 2018). An 
update of this model that included a systematic review estimated that Zambia had over 1,000 
NOTES: Source is WHO - reported incidence by country – Zambia.  
*Total confirmed cases reported. These include all cases confirmed by laboratory testing, or epidemiological linkage, 
plus those clinical cases that were reported without a laboratory specimen or epidemiologic linkage.  
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cases of CRS born per year (Vynnycky et al., 2016). In 2016, Zambia utilized GAVI funding to 
introduce rubella containing vaccine through a supplementary immunization campaign that 
covered 9 month-14-year olds, and subsequently replaced measles only vaccine in the routine 
immunization program.  
 A few serological surveillance studies have been conducted in Zambia prior to rubella 
vaccine introduction. In 1979, a serological surveillance study found 75% immunity to rubella by 
the age of 13 (Watts, 1983). More than 30 years later, another rubella serological survey tested 
donor blood for rubella IgG and found 91.9% seroprevalence among women older than 16 years 
of age (Mazaba-Liwewe ML, 2015).  This study found no association with sociodemographic 
factors such as economic status, education, marital status or urban/rural residence. The authors 
note that although they did not find an association with age, this could have been due to the small 
sample size of 124 women (M. L. Mazaba, Monze, Babaniyi, Siziya, & Michelo, 2015). 
In 2016, a retrospective serological survey used specimens of children 5-15 years old, 
collected for HIV and malaria studies and tested them for measles and rubella IgG. The objective 
was to compare the seropositivity of HIV uninfected children with HIV infected children, both 
on and naïve to antiretroviral therapy. This study found that a higher proportion of HIV-
uninfected children (92.5%) were seropositive for measles than HIV infected treatment naïve 
children (74.1%) and HIV infected on ART (71.9%). For rubella, 54.7% of HIV uninfected 
children were seropositive, compared to 41.7% HIV infected treatment naïve and 49.6% HIV 
infected on ART. For rubella, seropositivity significantly increased with age, suggesting that 
population immunity reaches over 80% by the age of 15 years (Sutcliffe et al., 2017). 
The results of these serological surveys in Zambia are in line with other African 
serological surveys which found 84-94% seropositivity to rubella among women of reproductive 
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age (Goodson et al., 2011). However, most of them used a small study population that was not 
nationally representative or covered narrow age groups. Little is known about the full age-range 
susceptibility profile of rubella in Zambia. Additionally, previous serological surveys used only 




Parent study: Strengthening Immunization Systems through 
Surveillance (SISS)  
 To address some of the methodological questions for serological surveys, the 
International Vaccine Access Center developed a project funded by the Bill and Melinda Gates 
Foundation to conduct research studies on these issues. The overall goal of the project is to 
assess the feasibility and utility of using serological data to monitor and guide immunization 
programs in low income countries. This includes addressing epidemiological, technical and 
operational issues to demonstrate the capacity to generate valid and timely serological data to 
guide routine, supplemental and targeted immunization activities. To accomplish this, SISS 
established demonstration projects in India and Zambia. In both field sites, research activities 
aim to answer operational research objectives for serological surveys that are generalizable, 
while taking into account specific country priorities (Figure 2).  




First serosurvey: ZamPHIA 
In early 2016, the Zambia Population HIV Impact Assessment (ZamPHIA) was 
conducted as a cross-sectional community survey to estimate HIV incidence and prevalence. 
This study collected survey data and venous blood specimens from adults 15 to 49 years of age 
in every household selected and children younger than 15 years of age in every other household, 
with dried blood spots collected from children under 2 years of age (Ministry of Health, Zambia, 
2017). This study was powered to estimate provincial HIV incidence by selecting enumeration 
areas in each province (Figure 3). This study reported 11% of households refused to provide 
blood specimen and only 68% of eligible children participated (Columbia University, 2016).  
After HIV testing was completed, residual plasma and dried blood spots from this study were 
frozen in a biorepository at -70°C at the Tropical Disease Research Center in Ndola, Zambia. 
Residual plasma and DBS samples from this study were tested for anti-measles virus and anti-
rubella virus IgG antibodies.  




Second serosurvey: nested within PCES 
 The second serosurvey to assess measles and rubella immunity was conducted as part of a 
post-campaign vaccination coverage survey conducted by the Ministry of Health in Southern 
Province, Zambia. Southern Province was selected based on administrative immunization 
coverage and the capacity of field and laboratory teams at Macha Research Trust, an existing 
field site established in 2003 that had been working on malaria and HIV research. The nested 
serological survey used the same sampling strategy as the post-campaign vaccination coverage 
survey. Twenty-six clusters were selected in Southern Province (Figure 4). Within these, 
households with children in the post-campaign vaccination coverage survey target age group (9 
months to less than 15 years) were eligible for enrollment in the nested serological survey. Dried 
blood spots were collected from participants 9 months of age and older to test for anti-measles 
virus and anti-rubella virus IgG antibodies. 




Introduction to dissertation 
In the following chapters, I present an introduction, methodology, results, discussion and 
conclusions separately for each of the three dissertation aims. Finally, a concluding section pulls 
together all the information and provides public health significance and next steps for future 
research. All papers are embedded in the parent study of strengthening immunization systems in 
Southern Province, Zambia. 
Specific aims 
1. Characterize factors that impact participation in serosurveys: This aim 
documented the barriers and facilitators to participating in community-based serological 
surveillance during the post-campaign coverage survey of measles and rubella. 
2. Cost of serosurveys: For this aim, we developed a costing framework for serological 
surveillance and estimated the costs of collecting serological specimens during a 
vaccination coverage survey to estimate population immunity levels for measles and 
rubella. 
3. Change in seroprevalence following a vaccination campaign: To assess the change 
in seroprevalence of measles and rubella pre and post-vaccination campaign from two 
serosurveys, we adjusted for different survey design methodologies. 
 
 Aim 1 documents the factors associated with participation in serosurveys from the 
perspectives of data collectors who participated in the nested serosurvey and caregivers who 
were in communities eligible to participate in serosurveys. We used the socioecological model as 
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a framework to characterize barriers and facilitators to serosurvey participation. Aim 2 adapts a 
framework from integrated disease surveillance to capture the costs of doing a serosurvey nested 
in a post-vaccination campaign survey. We captured costs by both input and serosurvey function 
to evaluate which factors contribute the most to the cost of serosurveys. We also vary the sample 
size parameters to estimate the effect on the cost of serosurveys.  
 Aim 3 uses two serosurveys conducted with different methodologies to estimate the 
change in seroprevalence before and after a measles-rubella vaccination campaign. We explore 
the adjustments and factors to consider when comparing two serosurveys that used different data 
collection and laboratory methodologies. Finally, we present the implications of serosurvey 
design and considerations for implementing future serosurveys. Each chapter addresses a 
different aspect of the feasibility of using serosurveys to monitor population immunity, and the 
discussion chapter ties together the implications for serosurveys. 
Data sources 
This thesis dissertation uses information from two different serosurveys: (1) ZamPHIA, a 
serosurvey that used a biorepository from specimens collected for an HIV study nationwide in 
the first half of 2016, and (2) a serosurvey conducted in November-December 2016 
simultaneously with a post-campaign vaccination coverage evaluation survey (PCES) in southern 
province. The first study includes specimens collected before Zambia conducted its nationwide 
measles-rubella vaccination campaign and introduced rubella containing vaccine; whereas the 














Quantitative epidemiologic data    
Laboratory data    
B) Post-campaign coverage survey (PCES) 
Quantitative epidemiologic data       
Laboratory data    
Budget information       
Qualitative data   
 
  
C) Post-introduction evaluation for measles-rubella vaccine 
Qualitative data 
 
    
 
Aim 1 uses qualitative data collected in two different phases. For the first phase we 
conducted focus group discussions and interviews with data collectors who participated in the 
PCES serosurvey. The second phase surveyed caregivers at health facilities who were present at 
the time of the post-introduction evaluation for measles-rubella vaccine in areas that were 
eligible to participate in serosurveys. They were interviewed about barriers and facilitators to 
serosurvey participation for both themselves and their families. Aim 2 uses the PCES serosurvey 
to estimate the financial costs of a serosurvey using an ingredients-based approach. Data sources 
included the serosurvey budget and program records and interviewing administrative personnel. 
Aim 3 analyzes laboratory results and epidemiological data from Southern Province in the two 




The ZamPHIA study was originally approved by the Zambian Ministry of Health. 
Testing of the biorepository was approved by the Johns Hopkins School of Public Health IRB as 
well as Zambian National Regulatory Authority. Written consent was provided by all 
participants for the original HIV testing, as well as whether they would allow their specimens to 
be stored for future testing. The post-campaign coverage survey received ethical approvals from 
the Zambian Ministry of Health, as well as IRB approval at Johns Hopkins School of Public 
Health and Macha Research Trust in Zambia and was approved by the Zambian National 
Regulatory Authority. Written informed consent and/or assent was obtained by all participants, 
as age appropriate. The post-introduction evaluation was approved by the Zambian Ministry of 




Paper 1- Acceptability of a serosurvey for 
vaccine preventable diseases in rural 




Background: The factors associated with whether individuals choose to participate in survey 
research are not well understood. Serosurveys may require additional resources to ensure 
participation because they collect biological specimens, often blood, from participants. 
Understanding perceptions from multiple perspectives, including the perspectives of both data 
collectors and participants through the socio-ecological model contextualizes individual, 
interpersonal, and structural level influences on survey research participation.  
Methods: We used a mixed methods approach to characterize reasons for serosurvey 
participation in communities in Southern Province, Zambia where a serosurvey was conducted in 
2016. For the first phase, we conducted focus group discussions and interviews with 24 data 
collectors who participated in a measles-rubella serosurvey in 2016. The second phase surveyed 
34 caregivers at health facilities to identify barriers and facilitators to serosurvey participation. 
Emergent themes from the data were then classified into a socio-ecological model using 
individual, interpersonal, and structural level constructs. 
Results: Common themes emerged from the data collectors as well as the caregivers surveyed. 
At the individual level, providing incentives was a motivator, and religion was described as a 
barrier to serosurvey participation. At the interpersonal level, family dynamics and community 
influences could help or hinder serosurvey participation; however, community health workers 
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were consistently named as facilitators of participation. At the structural level, concerns about 
specimen collection, who was selected to participate, and not receiving test results arose as 
potential barriers. The most frequent facilitator was provision of information about the purpose 
of the serosurvey (85%). The most frequent barrier was being unsure of what is being done with 
their blood (53%). For specimen collection type, caregivers preferred finger prick blood 
collection over both venous blood draw (59%) and oral swabs (71%). 
Discussion: Interpersonal relationships and structural issues related to serosurvey 
implementation were the key motivators for participation in a serosurvey. Provision of 
information ahead of the serosurvey to answer questions related to blood collection and 
communicating through a trusted vehicle such as the community health worker were particularly 
important to all participants. 





Recruitment and retention of a representative population is crucial to the validity of 
research studies, including population surveys. However, the factors associated with whether 
individuals choose to participate in research are not well understood. For some studies, such as 
clinical trials, reasons for participation can include direct individual benefits (Chatio et al., 
2016). However, beyond direct benefits, other reasons healthy individuals participate in clinical 
trials include altruistic reasons, community benefits, and a feeling of accomplishment by 
contributing to research (Dhalla & Poole, 2014). This belief in the societal benefits of research is 
also applicable in the context of survey research, whether there are individual or community 
level benefits.   
Conceptual models, such as the socio-ecological model, have been used to identify 
influences, such community-level influences, on research participation (Salihu et al., 2015).  The 
socio-ecological model posits that people’s behavior is determined not just by individual-level 
aspects but also by intrapersonal factors, interpersonal processes, institutional factors, 
community factors, and public policy (McLeroy et al., 1988). This interplay of factors can affect 
whether people participate in research, including the influence of social norms and community 
leaders (Nyaoke et al., 2017). The engagement of community and religious leaders through 
social mobilization has been recognized as an important component of community acceptance of 
survey participation (Travassos et al., 2015). 
Serosurveys may require additional resources for social mobilization because they collect 
biological specimens, often blood, from participants (Bryant Borders et al., 2007). Refusal rates 
may be higher for surveys that collect blood specimens than surveys that collect only 
questionnaire data due to potential discomfort, added time for specimen collection, or 
participants not trusting what is being done with their blood (MacNeil et al., 2014). To monitor how 
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non-participation could introduce bias, refusal rates for serosurvey participation are tracked and 
reported, as those who participate may be different than those who refuse. However, there are 
limited data explaining why individuals refuse to participate in serosurveys in sub-Saharan 
Africa (Travassos et al., 2015). 
To improve participation in serosurveys, better understanding is needed on how 
communities perceive serosurveys. Understanding perceptions from multiple perspectives, 
including the perspectives of both data collectors and participants, can provide a more 
comprehensive view on what influences participation.  We conducted a qualitative analysis to 
characterize reasons for serosurvey participation in communities in Southern Province, Zambia 




The study was conducted in Southern Province, Zambia, the third most populous 
province in Zambia with 1.6 million inhabitants (Zambia Central Statistical Office, 2012). The 
province is primarily agrarian, with a malaria prevalence of less than 1%, an estimated HIV 
prevalence of 13% among adults, and first-dose measles vaccination coverage of 86% (Zambia 
Central Statistical Office, 2014). The infant mortality rate is 44, compared to a national average 
of 45 (Zambia Central Statistical Office, 2014). There were at least two serosurveys conducted in 
different parts of Southern Province in 2016. In early 2016, an HIV incidence and prevalence 
survey, ZamPHIA, was conducted by collecting blood in a community setting; 11% of 
individuals participated in the survey but refused blood collection (Columbia University, 2016).  
In mid-2016, a serosurvey to assess measles and rubella immunity was conducted among 
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communities in this area as part of a vaccination coverage survey conducted by the Ministry of 
Health. This serosurvey collected dried blood spots from participants who provided written 
consent after being informed of the purpose of the study (Hayford et al., 2019). This serosurvey 
also included a sensitization plan to inform key stakeholders the purpose and procedures of the 
serosurvey. During the serosurvey, data collectors were assigned community health workers 
from the clinics who they were intended to coordinate with during the serosurvey.  Despite these 
efforts to ensure participation, 12% of individuals at enrolled households refused to participate in 
the serosurvey (Mutembo et al., 2018).  
  
Study Design 
We used a convergent mixed-methods design where qualitative and quantitative data 
were collected sequentially, analyzed simultaneously, and interpreted together. The study was 
conducted in two different phases in Southern Province, Zambia. The first phase was qualitative 
and was conducted immediately following the measles-rubella serosurvey in December 2016. 
We conducted in-depth interviews and focus group discussions with data collectors to evaluate 
the implementation of the serosurvey and their perception of community acceptability. The 
second phase was conducted in April 2017 among caregivers at health facilities in districts that 
were eligible to participate in the serosurveys. The cross-sectional survey consisted of questions 
related to what would motivate or prevent them from participating in a serosurvey.  
 
Participants and Data Collection 
In the first phase, the 36 data collectors who were part of the serosurvey teams were 
purposefully sampled to include representation of at least one member from each team that 
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participated in the serosurvey. From the personnel list, team supervisors were prioritized, and 
then data collectors who were involved in blood collection. Participants were recruited during the 
serosurvey and invited to participate immediately after data collection was completed. We aimed 
to include participants that had different roles on the team, and we stopped once data saturation 
was reached. Interviews and focus group discussion (FGD) guides included questions on how the 
data collectors were received by the community and perceptions of community acceptability of 
serosurveys. Interviews were conducted individually with supervisors so as to not influence non-
supervisors, and FGDs were conducted with non-supervisory data collectors in groups of 6-8 
individuals, with a local partner who specializes in qualitative research and was external to the 
serosurvey, to help facilitate. We obtained verbal consent from all participants. All interviews 
and FGDs were conducted in a private room and were done in English, audio recorded, and 
transcribed. Reflexive memos were written following each interview and FGD, as well as 
throughout the data analysis process. 
For the second phase, a convenience sample of caregivers attending health facilities were 
selected. During a two-week period, caregivers who were present at the health facility at the time 
of the supervisory visit were recruited by a healthcare worker in the waiting room. Participants 
were not required to have participated in a serosurvey previously, but facilities were in areas 
which were eligible to participate in the previous serosurveys.  It was reiterated during the oral 
consent process that the questionnaire would have no bearing on the care they received. The 
caregivers were asked questions related to the acceptability of blood collection in the 
community, including previous serosurvey participation, barriers and facilitators to serosurvey 
participation, specimen preference, and self-efficacy, the belief in one’s ability to make one’s 
own decisions. We used results from the first phase to develop the survey questions for the 
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second phase. Questionnaires were translated into Tonga and back translated. Questionnaires 
were administered in Tonga by a trained local collaborator in a private area in the waiting room 
of the health facility. All data were entered in a tablet and uploaded to a secure cloud server 
daily.  Debriefing meetings were held after questionnaires were completed at each health facility 
to review data quality. 
Ethical and regulatory approval was obtained from the institutional review boards at 
Johns Hopkins University School of Public Health and Macha Research Trust, and the study was 
approved by the Zambia National Health Research Authority. 
 
Data Analysis 
Qualitative data from the first phase were analyzed using a grounded theory approach in 
Atlas TI (version 10.1). Grounded theory allows the data to speak for itself without using a priori 
assumptions (Glaser, 1967). There were several rounds of codebook development as well as 
coding, including initial open coding to generate categories, followed by axial coding to relate 
these categories, and finally grouping by theory (Charmaz, 2006). Coding discrepancies between 
the two analysts were discussed until a resolution was reached. The constant comparison 
approach was used to generate themes through simultaneous coding and analysis (Glaser, 1967). 
Preliminary analysis of the themes that arose during the qualitative analysis of the first phase 
informed the development of the survey questionnaire for caregivers in the second phase.  
Quantitative data from the second phase were cleaned and analyzed using STATA 14.  
Descriptive statistics were performed to look at frequencies, and grounded theory was used to 
code the answers of open-ended questions in Excel. Quantitative and qualitative data were 
39 
 
initially cleaned separately and then analyzed together, classifying emergent themes into a socio-




Two focus groups were conducted with 13 data collectors, and 11 semi-structured in-
depth interviews with supervisors of the serosurvey teams were conducted (Table 5). 
Thirty-four caregivers were surveyed from 9 different health centers in 3 districts in Southern 
Province, Zambia (Table 6). These districts had also participated in the post-campaign coverage 
survey and serosurvey that took place in 2016. All participants were female. Most of the mothers 
were younger than 30 years of age (68%). The most prominent religion was Seventh Day 
Adventists (38%), which does not permit blood collection. Almost half of those surveyed 
reported having traveled for longer than one hour to arrive at the health facility. Most of the 
caregivers were at the facility to bring their children to the vaccination clinic, most of whom 
were under five-years of age (91%). 
Ten caregivers (29%) reported having participated in a household-based survey in the 
past. These included surveys for different health purposes including malaria, HIV, and sanitation. 
Of those, eight caregivers (80%) reported that the surveys collected blood or saliva, about half 
(50%) received their test results, and three caregivers (30%) had taken part in more than one 
household survey. When asked directly if they would allow finger prick blood collection at their 






Results were categorized by acceptability factors that affect participation in serosurveys, 
including barriers and facilitators at each socio-ecological model level: individual, interpersonal, 
and structural. Individual influences included personal motivation such as incentives and 
religious beliefs. Interpersonal influences affecting participation in serosurvey decision making 
included community, family structure, and the community health worker influence on 
participants. Finally, structural influences included factors associated with survey 
implementation. These included questions related to specimen collection, including specimen 
preference type, who is asked to participate in serosurveys, and provision of test results. These 
acceptability themes are summarized by socio-ecological model level in Figure 5 and presented 
below.  
 
Acceptability: Individual Influences  
According to survey results, there were individual motivators classified as facilitators that 
encourage serosurvey participation including incentives, altruistic notions, and the personal 
desire to know more about health issues (Table 7). Similarly, data collectors noted participants 
wanted compensation for their participation. Religious beliefs were mentioned as a barrier to 
specimen collection by both the caregivers and the data collectors. 
 
Incentives 
Data collectors identified compensation as a specific individual level incentive. One data 
collector remarked:  
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We discussed (incentives) in workshop. That it would look as if we were paying for blood, 
but people really wanted to be compensated for their blood. 
Data collectors noted that even if payment could not be made so that participation would not be 
perceived as coercive, compensation of some form was asked for by participants, as evidenced 
by this data collector: 
On the same collecting blood, others were saying, ‘you should compensate us’. Simple 
stuff like a drink, milk. That’s what normally happens when others go out to collect 
blood. So why are you not compensating us? 
 
Religion  
Religious beliefs were primarily described as a barrier to serosurvey participation due to 
blood collection, as mentioned by 15 caregivers (44%). Zionism, a religious sect that does not 
believe in Western medicine ("Zionism," 2019), and Seventh Day Adventists were mentioned as 
religions that did not allow provision of blood specimens. Two caregivers also mentioned 
satanism, the worship of Satan or obsession with evil, as a barrier to blood collection. Many of 
the concerns that data collectors reported related to traditional beliefs that blood was used for 
witchcraft and satanic rituals, as articulated by this data collector: 
You know, the people, they think that when you get blood from them, maybe you want to 
do rituals on them. That’s what affected mostly the blood collection. And there are some 
areas where they believe really too much into satanism. 
Data collectors reported being told that they were not welcome to collect blood because 
community members held the belief that data collectors themselves were Satanists.  
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When you start explaining to them [why we are here], they get surprised and some were 
even chasing us, telling us, “Go!”, “Why do you want our blood? You are just 
Satanists!”  
Despite reports of the community calling data collectors Satanists, a supervisor pointed out she 
did not believe there was a prominent satanic community in the areas where the serosurvey 
occurred.  
The belief around here was, they were like, maybe you want to…. offer my blood as a 
sacrifice. Maybe you are Satanists. Yes. They believe in Satanists collecting blood from 
people. 
Facilitator: Does that happen a lot here? 
They’ve never even seen it. Neither have I. So [satanism] is just rumors. 
 
Acceptability: Interpersonal Influences 
The decision of whether or not to participate in a serosurvey falls under a broad 
healthcare decision making umbrella. Survey participants identified several interpersonal 
influences on healthcare decision making, including themselves, family members, and 
community health workers (Table 7). Data collectors similarly mentioned family members and 
community health workers as interpersonal influencers, but also added the belief that community 
norms and specific community members influenced individual choice to participate. With 
regards to interpersonal influences, both caregivers and data collectors noted the importance of 
providing information about the objective of the serosurvey and having this come from someone 





Family dynamics played a role in potential serosurvey participation, as noted by 14 
caregivers (41%) who cited fathers or grandparents as influencing their healthcare decision 
making process. Data collectors also noted that permission from caregivers to allow children to 
participate in the serosurvey was challenging in some areas because mothers required permission 
from the fathers, or even tried to have their children participate but the fathers refused by even 
hiding children, as told by this data collector:  
The husband said, “no, I cannot do this.” The wife… wanted to participate, but the 
husband got one of the children [and took] him in the house. Again, [he] called another 
[child], and sent to get another [child]. The mother was like, “what do I do now?” 
In addition to the need for approval from the child’s father, data collectors stated that women 
also needed to be present for a child to participate in the serosurvey. This is because mothers 
have the information to answer the questions regarding vaccination history, as noted by this data 
collector:  
I guess that made me understand that the men that head the households don’t really have 
enough information on their children and their children’s health.  
Additionally, older children, even young adults, tended to default to the decision of their parents 
as to whether they participated in the serosurvey, as this data collector relayed:  
Generally, if the parents refused…even if the kids [were] 15-16 [years old]…they would 
say dad doesn’t want [them to participate]. We’d find maybe even 18-20 [years old], they 
would accept because we told them what the survey was about, but if daddy says none of 
my children, they would also back out. They were adults, but they start off saying no 





Data collectors highlighted the influence of the community on serosurvey participation. 
For areas where there were refusals, it seemed there had either been poor social mobilization 
efforts or community sensitization was insufficient. One data collector relayed to us the thought 
process of participants in a community where she believed they had gathered to make a 
collective decision on participation in the survey:  
For example, you visit me at this house. You also visit the other house. If I’m not clear, 
I’ll go and ask my neighbor, ‘did you hear what these people say?’ And sometimes the 
community will want to meet. ‘Let’s do this when they come, let us all refuse.’ By the time 
you go, you try here, you try there. Like one village where we went, everyone refused. 
And we definitely knew these people could have had a meeting after we passed yesterday, 
they met. 
Some data collectors reported that communities said they could not participate because the 
village headmen and local health facilities had not been informed of the survey, indicating 
community leadership served as gatekeepers to serosurvey acceptance:  
Their concerns were…if it’s from the Ministry of Health, they always pass through the 
clinics, or the health centers/facilities to say or to announce to the community to say if 
you come on such and such dates to the clinic, there will be this. Yes, they know. So the 
villages, the headmen, most of them, they were not aware. So they were like, we cannot 





Community health worker 
Another influence in the acceptability of serosurvey participation was the community 
health worker (CHW). Among caregivers, one-third had received health information from 
community health workers, including information about vaccination. CHWs were viewed as 
important facilitators by both data collectors and caregivers for two primary reasons: they were 
recognizable by the community, and they were a source of trusted information.  
Caregivers articulated that it was important to have someone they recognized on the 
survey team, as this was an important factor in deciding whether or not to participate in a 
serosurvey:  
The people doing the surveys must go through the health center and come with people 
from the health center. Then we know they are real. I would not accept unless you come 
with someone I know from the health center. 
This sentiment of having someone the community trusts was named as a facilitator to serosurvey 
participation by one-third of caregivers. 
Overwhelmingly, data collectors agreed that having a CHW accompany the serosurvey 
teams was helpful for both knowing where to go in the community as well as sensitization of the 
community. One data collector noted: 
At the clinic [we picked up] the health worker, and... the community health worker. We 
used to move with the two of them. [When] we would go to certain households, [the 
community health worker] was the one who first, started introducing us, so it was a bit 
easy. 
Almost all caregivers (85%) reported that the provision of information about the purpose of the 
serosurvey was the primary facilitator to encourage participation. This sentiment was echoed by 
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data collectors, who recommended sensitization in the communities ahead of time, as mentioned 
by this data collector: 
Because most of the people in rural areas are illiterate, so it’s very difficult for them to 
understand when you go there to explain something. Even if you explain something in 
depth, they will keep on asking you the same question. So if they visit them, they 
explain…maybe it can be easier when other people come in now to do surveys in their 
areas. 
Data collectors believed that providing information in advance about the serosurvey to the 
communities facilitated implementation in some areas, as noted by another data collector: 
[For] sensitization I think it’s also important to give the correct information to people 
who are requested to go in the community to sensitize. It would make the work very easy. 
Community health workers should be the ones to provide the information about the purpose of 
the serosurveys to improve participation, as highlighted by this data collector: 
I think the best thing to do is, those places...if they can make use of the CHWs to sensitize 
them. So that when there’s such a program, the people are aware, and they know the 
reason why people travel from distant places to go to their places to do such programs. 
Because the level of understanding is what is lacking. 
 
Acceptability: Structural influences 
Structural issues were among the most common themes. Among data collectors, 
structural level influences on participation were related to specimen collection, including amount 
of blood and where blood was being taken; who was selected to participate and who was 
excluded; and desire for test results. In the caregiver survey, being unsure of what was being 
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done with the blood and fear of test results arose as significant barriers to participation (Table 7). 
Both the qualitative and survey data indicated that receiving test results was an important 
facilitator to serosurvey participation. While questions about selection criteria for participation 
did not arise in the survey data, caregivers did mention that multiple researchers working in the 
area was a barrier. Both qualitative and survey results specifically referenced HIV testing as a 
concern for serosurvey participation; however, data collectors also noted that some participants 
desired HIV testing. Structural level barriers and facilitators were grouped into issues related to 
specimen collection, selection criteria for participation, and the results of testing.  
 
Specimen Collection 
Barriers named by both caregivers and data collectors were primarily centered on issues 
with specimen collection. Most caregivers (53%) listed lack of trust in what was being done with 
the blood as the primary barrier to participation. Similarly, data collectors mentioned that 
potential participants asked many questions despite being explained during the consent process: 
“Why are you taking our blood? Why are you studying this?”  There were also some questions 
related to rubella virus, the vaccines, and how antibodies worked.  
In the qualitative data, data collectors noted comments about specimen collection related 
to past experiences with serosurveys. In areas where the community had participated in an HIV 
serosurvey earlier that year, some of the questions that arose were related to their experience 
with that survey. One supervisor noted the amount of blood as a concern. 
Before consenting, they really wanted to know how much blood we were collecting. They 
were referring to previous survey…They were saying ZamPHIA collected a lot of blood, 
so how much are you collecting from us. 
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The primary concern that data collectors noted from the community was “Where are you taking 
our blood?” As one supervisor highlights, this concern refers to a previous serosurvey: 
In general, they were just asking, where the blood is being taken. Because…the last 
survey which happened for ZamPHIA, they were collecting about 14 mL of blood, which 
they were using to test HIV, syphilis and hepatitis B. So, people were actually concerned 
about that one. So when you just mention blood, they would be like, where do you take 
our blood?.... They would ask a lot of questions over the blood that was taken. 
In terms of where specimen collection should occur, the survey found that half of caregivers 
thought having people come to a central location, such as a clinic within the community, would 
facilitate serosurvey participation. 
 
Selection criteria 
In terms of who is selected to participate in serosurveys, both caregivers and data 
collectors mentioned concerns about the same communities being repeatedly asked to participate. 
One caregiver listed too many researchers coming to collect blood from the community as a 
barrier. This sentiment was echoed by the data collectors, as noted by one:  
Mostly people go there to collect blood. Different programs, from MOH [Ministry of 
Health]. So every time it’s just blood, blood, blood... 
In the qualitative data, data collectors noted additional concerns from the community as to why 
certain people were being included in the survey and others excluded. In some cases, this was 
from participants who were selected for the serosurvey, asking why everyone was not being 
included. In other cases, it was community members wanting to participate, and asking why they 
were being excluded. Both experiences are mentioned by this supervisor: 
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You would find that the household that you…pick. Those that were picked will say, “why 
us? Why are you not getting everyone?” So sometimes you would find that those that are 
left out, like, “why have you left us?” There was someone [who] got upset. “We’ve left 
our work. We’ve stayed [home]. We stopped what we were doing, and…you are not 
going to include us.” 
Similarly, data collectors said community members from rural areas asked why they were 
targeted, when people in urban areas were not. 
…Others were saying why is it that you always come in the rural areas? When we phone 
our relatives in town, they say they don’t experience such things. 
There was also a question about why older individuals were being included, when they had not 
received the vaccine, as mentioned by this data collector: 
Then the other question was, why are you selecting households, not collecting blood from 
everyone who was given an injection. Or that vaccine you are saying. And why are you 
collecting blood from everyone, including the oldest, when they didn’t receive those 
vaccines. 
These concerns about equity of selection did not arise in the caregiver survey. 
 
Test results 
The issue of test results was viewed as both a barrier and a facilitator, depending on the 
context. In the caregiver survey, fear of test results because they fear being told they have a 
disease was a substantial barrier to serosurvey participation (41%), yet all said receiving their 
test results was important to them (Table 7). The data collectors also noted the community 
valued receiving their test results. Although HIV testing was not specifically asked in either the 
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caregiver survey or as part of the qualitative data collection, it arose as an important theme. 
There were reports of participants wanting to be tested for HIV as well as refusals to participate 
in serosurveys for fear that they would be tested for HIV. Finally, the data collectors also 
mentioned privacy as a concern from participants who feared their test results would become 
known. 
A sub-theme within test results focused on receiving test results. Receiving the results of 
any testing done on specimens was noted as important by both the data collectors and caregivers. 
All caregivers agreed that receiving test results was important to them, and a few said that not 
receiving their test results was a barrier to serosurvey participation. Additionally, 79% stated 
they were willing to accept summary-level results at the district level rather than individual test 
results. 
Just as test results were reported as important to caregivers, the most commonly 
referenced requests from the qualitative data was the community wanting to know the results of 
the testing being done on their blood. Data collectors reported complaints from the community 
that data collectors in the past collected blood from them but did not provide test results. As 
noted by one supervisor from the serosurvey: 
After sensitizing them, they gathered to refuse…say[ing] ‘there are a lot of people 
coming to take our blood. They don’t come back to tell us our results in person.’ 
Everyone wants to know their results. Sometimes you say after pricking [you will get 
results], they say ‘no, give us our blood back.’ They say ‘you are doing for everyone in 
this community. We want our results. You just come, you don’t bring us anything.’ 
A data collector also reported anxiety from the community over receiving their test results: 
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I think the community is also anxious to know their results. Because most of the time, 
these studies are being done, but the response is not taken back to the community. 
One data collector also specifically noted that not receiving test results negatively affected the 
community’s willingness to participate in the study: 
The biggest question that we faced was…most of the time, we go to them to collect blood, 
but we don’t tell them the outcome. When we collect blood from them, when we go, we 
[leave forever], without even informing them what we have found. So now they were like, 
‘you people, us we are very much willing to participate in this program. But the problem 
that we have is every time you come, you collect our blood, you go. But when it comes to 
giving us the results, you don’t even tell us what you find.’ That was their main concern. 
 
A second sub-theme that emerged within test results focused on HIV testing. This sub-
theme arose in both the caregiver survey and data collector qualitative data. Almost half of 
participants feared learning their test results, and some thought there could be stigma related to 
having their blood collected. While not explicitly stated by all, there were undertones of HIV 
testing in the open-ended responses. One caregiver mentioned long-term treatment despite lack 
of symptoms: 
People scared of that they will be found with a disease and be put on treatment when they 
feel okay. 
While another caregiver stated:  
They fear to know their (HIV) status. 
Finally, another caregiver specifically stated fear of stigma about HIV if they participate: 
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They do not want to be seen that they had their blood collected. Because then others will 
suspect that you have a disease such as HIV. 
Similarly, data collectors also mentioned that people thought blood was being collected for HIV 
testing. In some cases, it was reported that community members wanted to get tested and had a 
desire to be included in the study to know their HIV status. As noted by one data collector: 
People were running to the car and stopping the car, “we want to be tested for HIV.” 
And we were saying, “no we are sorry. We don’t have kits as for now, but you can go at 
the nearest clinic.” And they said, “oh, we thought you were even testing for HIV.” So we 
were just advising them to go at the clinic to have their HIV test. Otherwise they were just 
like, “no, we want HIV test.” [We said] “No, it’s not what we are after. We were after 
measles.” 
Conversely, data collectors also reported there were concerns from those asked to participate that 
their blood would be tested for HIV, despite being told this was not the case. Another data 
collector mentioned: 
They would also think maybe if you don’t [give] much information [about the study] that 
we are not testing HIV, they would think…you want to find out about our status. So it was 
vital again to introduce that, to say that, okay we are not testing this (HIV). 
 
The final sub-theme within test results focused on privacy. There were community 
concerns noted by data collectors, related to test results being made public. This concern tended 
to arise during the informed consent process.  
The question… “why are we signing the consent forms? Why are you taking our names?”  
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There was also a concern that their test result would become known. Participants pointed out that 
if the survey was anonymous, then names should not be required for participation. 
So [they ask] questions like, “how am I going to know that you are not going to testing 
my blood?” Even the consenting part… [I would say] I’ve just written your first name. If 
you are Richard, imagine how many Richards. I’ve written here [participant 
identification number] just of those, it’s just numbers. There was even this woman said, 
“but you asked for my name, then you’re saying you won’t publicize my rubella results. 
So why is my name for?”  
 
Specimen Preference 
Specimen preference was specifically asked in the caregiver survey and not directly 
mentioned in the qualitative interviews. The survey demonstrated that participants tended to 
prefer finger pricks over venous blood draw (59%) and finger pricks over oral swabs (71%); 
however, there did not seem to be a strong preference between venous blood draw and oral 
swabs (Figure 6). General reasons for specimen preference included simplicity of the procedure, 
pain caused by the procedure, a desire to know their test results, and choosing a specimen based 
on the doctor’s recommendation (Table 8). One-third of participants believed it was easier to 
have blood taken than saliva, while a few thought saliva was easier to collect. This could in part 
be due to participants saying they had never heard of testing from saliva. As noted by a 
caregiver, they knew diseases could be detected in blood: 
The doctor can detect a lot of diseases in blood, but I don't know if he can detect anything 
in saliva. 
Similarly, another participant noted that they had experience with blood draws and finger pricks: 
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I have never had a mouth swab before so I wouldn’t know how it works. I am familiar 
with a blood draw or pricks. 
Overall, caregivers mentioned more familiarity with blood draws and finger pricks than with oral 
swabs. 
Discussion 
This study provides two perspectives on the acceptability of serosurveys in rural southern 
Zambia: the data collectors and potential serosurvey participants in the form of caregivers. We 
characterized the motivators and barriers behind why participants are willing to participate in 
serosurveys. As demonstrated by the socio-ecological model, individual level factors were not 
the driving motivators, but rather interpersonal relationships, and perhaps most importantly, 
structural issues related to serosurvey implementation.  At the interpersonal level, familial input 
was important to decision making, and community healthcare workers were an important driver 
to participation because they provided information about the serosurvey and were trusted by the 
community. At the structural level, understanding use of specimen collection and provision of 
test results were key motivators for participation. Capitalizing on these motivators can help 
frame messaging for communities to improve participation in serosurveys. 
The socio-ecological model framework and providing both the data collectors and 
participant perspectives in this study enabled us to better understand the drivers and barriers to 
participation (Protiere et al., 2017). We were able to note certain differences in themes that arose 
at the interpersonal and structural levels. Caregivers said that they were the most significant 
decision makers; whereas the data collectors thought community norms were a major influencer 
in the acceptability of the serosurvey, including religious and community leaders. At the 
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structural level, questions about equity of participation arose from data collectors, regarding who 
was being chosen to participate in the serosurvey, with some groups feeling targeted, while 
others felt excluded. There were also privacy concerns about test results becoming known that 
arose from the data collectors. These likely did not arise in the caregiver survey, as people were 
not actually being asked to participate in a serosurvey. Privacy concerns have been noted for 
other studies that require dried blood spot collection (Hendrix, Meslin, Carroll, & Downs, 2013). 
Similarities between data collectors and participants included religion being an important 
individual-level barrier, community health workers as a major interpersonal-level facilitator, and 
questions about specimen collection and not receiving test results as a barrier at the structural 
level. Whether HIV testing was being performed was also mentioned as both a facilitator and a 
barrier from both perspectives. 
Addressing the barriers and facilitators to participation can reduce bias in serosurvey 
results. For example, it was noted that religion is a major barrier because Zionists and Seventh 
Day Adventists cannot provide blood specimens. If they are also groups that do not allow 
vaccination, the serosurvey will overestimate population immunity because they are not 
represented in the sample. Others who may not participate are those who are not home when 
sensitization occurs by the community health worker or when the actual survey is implemented. 
These could be households who work outside of the house or migrant families. In order to 
overcome this structural-level barrier, revisits or off-hour visits would need to be made to ensure 
they are included in the serosurvey (Salihu et al., 2015).  
Selection bias may also occur in terms of motivation for participation in serosurvey, such 
as a desire to know test results. It was uniformly agreed that it was important for participating 
communities to receive test results, either individual results or community-level results. While 
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there were some contradictions in that participants feared receiving test results if they did not 
feel sick, this did not seem to be for measles and rubella testing. Provision of test results has been 
noted as a factor for participation in blood draws in clinical trials (Chatio et al., 2016). In 
HIV/AIDS and malaria research, where point of care tests are available, test results can be 
provided immediately; however, for measles and rubella this is not yet an option, so other means 
of providing feedback would be required. For this reason, we asked if providing community-
level feedback would be acceptable, and 79% stated this would be amenable to them. Options to 
providing community feedback could include community-wide meetings, or meetings with 
community leaders or community health workers to provide aggregate results. 
As noted by both the data collectors and caregivers, there were participants who were 
both encouraged to participate by HIV testing, as much as there were participants who were 
discouraged from participating because they did not want to be tested for HIV, despite HIV 
testing not being part of the testing procedure for the serosurvey. Similar concerns of HIV testing 
of biological specimens have been noted in clinical trials in Africa (Chatio et al., 2016). Given 
the logistic and ethical issues with providing HIV testing, understanding the preferences of the 
community on HIV testing would be important to balance acceptability and feasibility of 
serosurveys. 
Although the focus of this paper is on the acceptability of serosurvey participation, there 
were some issues that arose that are generally applicable to all household surveys. In Table 7, 
most of the barriers named by caregivers were specific to serosurveys; whereas the influences 
listed as facilitators were general survey participation recommendations to improve acceptability. 
Similarly, all the interpersonal influences on serosurvey acceptability were general survey 
participation issues. Using a community health worker who the community knows and trusts has 
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been associated with increased likelihood of participation in research (Okello et al., 2012; Salihu 
et al., 2015) . Similarly, fear and distrust of research are barriers to research participation 
(Moreno-John et al., 2004). At the structural level, selection criteria for participation is also 
applicable to surveys in general.  
By contrast, the issues that were specific to serosurveys were religion preventing 
specimen collection at the individual level, and test results and questions about specimen 
collection at the structural level. Not knowing what would be done with blood specimens is a 
common barrier to research participation (Nakalembe, Mutyaba, & Mirembe, 2016). As noted by 
caregivers, the most frequently provided solution to overcome questions about specimen 
collection was to provide information to the community, which is a facilitator for all surveys. 
Religion as an individual barrier to participation can be overcome through community education, 
including engagement of religious leaders (Machekanyanga et al., 2017). The second most noted 
facilitator was to gather everyone in one location for specimen collection, which is specific to 
serosurveys. Because blood collection can be viewed as a medical procedure, conducting it at the 
household may not be as acceptable as doing so in a more central, sterile location (Ostermann et 
al., 2015). Understanding how much dropout occurs when blood collection is added to the 
survey, as compared to what dropout would have been without blood collection is an important 
consideration for serosurveys. 
In terms of specimen preference type, finger prick blood collection was notably preferred 
by caregivers. This finding is consistent with another study in Zambia that also reported 
preference for finger prick over venous blood collection by both participants and providers 
(Sutcliffe et al., 2017). By contrast, a study in Tanzania found that community members 
preferred venipuncture over finger prick blood collection (Ostermann et al., 2015). Our study 
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results indicated that blood was likely preferred because participants knew it as an effective 
means of detecting disease; whereas saliva was unfamiliar to most participants. The study 
population opinions are likely influenced by the fact that there are programs and research studies 
monitoring HIV/AIDS and malaria in the area (Columbia University, 2016; Larsen et al., 2015). 
Therefore, participants may be accustomed to receiving finger pricks for rapid testing, as noted 
by one third of caregivers having participated previously in a survey with specimen collection. 
The question of self-collection of finger prick blood was also asked but needs further study, as 
this was theoretical and not asked of every participant. This has been explored for HIV self-
testing, where users generally found self-finger pricking to be acceptable (Knight et al., 2017). 
Although we provide the community perspective by having surveyed caregivers directly, 
they are not caregivers who had necessarily participated in a serosurvey. They were asked 
theoretical questions about whether they would participate; though 30% had participated and 
there was no difference between the responses of those who had versus those who had not 
previously participated in serosurveys. Furthermore, there could be selection bias, as caregivers 
were recruited at health facilities, which may make them more likely to accept specimen 
collection because they engage with the healthcare system. Almost all the caregivers who had 
participated in previous surveys with specimen collection were for HIV/AIDS or malaria. There 
was also a prominent undertone of HIV/AIDS concerns underlying the responses in this 
population, such as fear of their ‘status’ or being put on treatment when they do not feel sick. 
Whether this is due to direct association with blood specimen collection, previous serosurvey for 
HIV, or social mobilization campaigns is not known. Finally, these results reflect a setting with 
high HIV and malaria transmission, which is accustomed to blood collection for diagnostic 
purposes, so our findings may not be generalizable to other settings. Despite these limitations, 
59 
 
our study is among the first to elucidate factors, both facilitators and barriers, to serosurvey 
acceptability.  
Conclusion 
Overall, serosurvey participation was deemed acceptable to most study participants. 
Refusals can be minimized by understanding the motivators and facilitators in the community in 
order to prevent high refusal rates. The socioecological model reveals barriers and facilitators for 
participation to guide strategies to improve participation. Specifically, planned serosurveys 
should make provisions to provide information about blood collection ahead of the serosurvey 
and communicate through a trusted vehicle such as the community health worker. If assessment 
is done to evaluate context-specific influencers of acceptability, it could help to guide strategies, 




Tables and Figures 
Table 5. Characteristics of data collectors who participated in in-depth interviews and focus 
group discussions 
  n=24 % 
Role     
Supervisors 11 45.8 
Data collectors 13 54.2 
      
Male 8 33.3 
      
Districts covered per team     
Kazungula, Livingstone 6 25.0 
Choma, Kalomo, Namwala 5 20.8 
Choma, Pemba 4 16.7 
Gwembe, Monze 6 25.0 
Province level 3 12.5 
 
Table 6. Sociodemographic factors and serosurvey response characteristics of caregivers who 
participated in the survey 
District n=34 % 
Namwala 12 35.3 
Kazangula 11 32.4 
Choma 11 32.4 
Religion     
Catholic 7 20.6 
Pentecostal 3 8.82 
Protestant 4 11.8 
Seventh Day Adventist 13 38.2 
Other 7 20.6 
Time to vaccination clinic    
<30 minutes 8 23.5 
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30-59 minutes 10 29.4 
60+ minutes 16 47.1 
Who influences decision making*   
Self 23 67.65 
Family 14 41.18 
Healthcare worker 5 14.71 
Community healthworker 2 5.88 
Chief or leader 0 0 
Participated in surveys n % 
No 24 70.6 
Yes 
If yes, type of survey: 10 29.4 
     HIV 4 40.0 
     Malaria 5 50.0 
     Sanitation 1 10.0 
     Doesn't remember 2 20.0 
Bodily fluid collected 8 80.0 
     Results received 5 62.5 
Number of surveys in which participated   
 0 1 10.0 
 1 6 60.0 
 2-4 3 30.0 
Willingness to participate in future serosurveys 
Willing to allow finger prick 25 73.5 
Willing to allow child’s finger prick 21 61.8 





Table 7. Caregiver barriers and facilitators to serosurvey participation (n=34)* 
Barriers n % 
Unsure what is being done with blood 18 52.9 
Religious beliefs 15 44.1 
Scared to know results 14 41.2 
Not getting test results 4 11.8 
Fear of needles 4 11.8 
Stigma 3 8.8 
Satanism 2 5.9 
Safety concerns 2 5.9 
Research fatigue 1 2.9 
Facilitators 
  
Information provided 29 85.3 
Have people come to central location for serosurvey 16 47.1 
Someone community trusts (like CHW) 10 29.4 
Desire to know about health issues 10 29.4 
Community thinks they will get a benefit 4 11.8 
Go house to house for serosurvey 1 2.9 
Desire to better society 1 2.9 




Table 8. Reasons for preferring a specimen type (n=34) 
Reason for preference* n % 
Simplicity of procedure 8 23.5 
Pain from procedure 8 23.5 
Desire to know test results 7 20.6 
Doctor recommendation 5 14.7 
Amount of blood 4 11.8 
Blood is better than saliva 9 26.5 
Saliva is better than blood 3 8.8 
Never heard of saliva testing 5 14.7 
Notes: (*) Participants could provide multiple reasons for their specimen preference 







Figure 6. Pairwise specimen preference among caregivers comparing oral swab, venous blood 
and finger prick collection methods 
 
Notes: (n=34) Participants were asked pair-wise specimen preference types, and stated either: 
preferred, no preference, or did not prefer one specimen over another. Only one response 




Paper 2- How much does it cost to measure 
immunity? A costing analysis of a measles 
and rubella serosurvey in Zambia  
Abstract 
Background: Serosurveys provide a more direct measurement of population immunity to 
infectious diseases such as measles and rubella than vaccination coverage; however, there is 
concern that serosurveys are costly. To better understand the costs associated with conducting a 
serosurvey, we adapted a framework that includes calculating personnel, data collection and 
laboratory costs.  
Methods: We costed a nested serosurvey that was conducted in Southern Province that involved 
collecting dried blood spots from households in a post-campaign vaccine coverage survey. The 
financial costs were estimated using an ingredients-based costing approach from the 
government-funded healthcare perspective over a two-month horizon. Program cost data were 
obtained from the serosurvey budget, program records and interviewing administrative 
personnel. Inputs included personnel, transportation, field consumable items, social mobilization, 
laboratory supplies, and capital items, and were classified by serosurvey function (survey 
preparation, data collection, biospecimen collection, laboratory testing, coordination). Inputs 
were also stratified by whether they were general to surveys or attributable specifically to 
serosurveys. Finally, we calculated the marginal cost per cluster and participant to vary 
serosurvey sample sizes and estimate the effect on cost. 
Results: We estimated that the total serosurvey cost in Southern Province, Zambia was US 
$68,558 to collect dried blood spots from 658 participants. Personnel costs were the largest 
contributing input to overall serosurvey costs (51%), transportation was second (23%), and field 
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consumables was third (9%). Data collection in the field accounted for almost one third of the 
total serosurvey cost (32%), followed by survey preparation (25%) and biospecimen collection 
(20%). By combining the serosurvey with the vaccination coverage survey, there was a savings 
of $43,957. In our nested serosurvey, the cost ratio (marginal cluster cost/marginal participant 
cost=$1,620/$30) was 54, reflective of a much higher cost to add a cluster as compared to adding 
an additional participant within an existing cluster. 
Discussion: We estimated that the added time for biospecimen collection in the field and 
laboratory-related supplies were only 36% of the overall serosurvey budget. Similarly, our 
survey identified personnel and transportation as the highest cost inputs; however, we were able 
to save $26,539 in personnel and $13,410 in transportation by nesting within the post-campaign 
vaccine coverage survey. Using an existing biorepository rather than collecting new 
biospecimens could result in cost-savings in the areas of data collection and biospecimen 
collection, which together account for more than half the cost of the serosurvey. Understanding 





Monitoring population immunity to measles and rubella viruses can help identify 
populations at risk of outbreaks and determine whether targeted vaccination efforts are needed. 
While vaccination coverage may be used to approximate population immunity levels, vaccinated 
individuals can remain susceptible and unvaccinated individuals can be immune following 
infection. Serosurveys provide a more direct measurement of population immunity to infectious 
diseases such as measles and rubella (Cutts & Hanson, 2016). With the establishment of many 
regional measles and rubella goals by 2020, the use of serosurveys to identify population 
immunity gaps has been increasing globally (World Health Organization, 2015). However, there 
is concern that serosurveys are costly and time consuming (Metcalf et al., 2016). WHO measles 
and rubella serosurvey guidelines are currently being developed and suggest it could cost from 
$100,000 to over $1 million and require a one-year timeline to conduct a serosurvey (Patel, 
2016). Understanding what drives the cost of serosurveys can shed light on how costs could be 
minimized. While many serosurveys have been conducted in developed countries, reducing cost 
could make them more accessible to low- and middle-income countries (Thompson & 
Odahowski, 2016).  
Some of the costs of serosurveys would be required for any survey, regardless of whether 
they include biospecimen collection or not, such as vaccination coverage surveys or 
Demographic & Health Surveys (Keogh, 2005). These include data collection costs such as 
travel and fieldwork including participant enrollment and questionnaire administration. (Luman 
et al., 2007). Adding specimen collection to a planned survey could result in cost savings; 
however there are concerns about logistical feasibility, cost implications, and survey 
implementation (MacNeil et al., 2014). 
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Another  major driver of cost is the sample size of a survey, which is influenced by the 
prevalence of what is being estimated and the precision of the estimate (Turner et al., 1996). 
Sampling strategies contribute to the cost of surveys differently, and understanding the 
implications of sampling on serosurveys could help determine their feasibility (Parker & Cubitt, 
1999). For example, if biospecimens could be collected from a subset of participants within a 
larger survey, this could help minimize costs. 
On the other hand, there are some costs that are unique to serosurveys because they 
require biospecimens. Serosurveys can prospectively collect biospecimens in the field or use 
specimens that have already been collected, such as a biorepository or residual samples. While  
prospective specimen collection allows for better control of data collection and sampling 
methodologies, collecting, processing and transporting blood specimens can be expensive and 
logistically challenging (Bryant Borders et al., 2007; Metcalf et al., 2016).   
One of the reasons that biospecimen collection can be challenging is that it can require 
trained and skilled workers or healthcare professionals.  This can vary depending on the type of 
biospecimen collected. For example, finger prick blood collection can be done by trained 
community health workers; whereas venous blood collection would require a phlebotomist or 
healthcare professionals (Harvey et al., 2008; World Health Organization, 2010). Biospecimens 
will always require specimen collection supplies, storage and transport, laboratory testing, and 
additional human resources for laboratory processing and testing (MacNeil et al., 2014). 
To better understand the costs associated with conducting a serosurvey, we adapted a 
framework developed to cost integrated vaccine-preventable disease surveillance that includes 
calculating personnel costs and laboratory costs (Toscano et al., 2013). We populated the 
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framework with data from a serosurvey conducted in Southern Province, Zambia to examine 
how different components of the serosurvey affect the total cost. 
Methods 
 
Study location and design 
This study was conducted in Zambia, where measles and rubella remain endemic, and 
cases continue to be reported annually (Zambian Ministry of Health, 2019a). Following a 
measles-rubella vaccination campaign in 2016 for children younger than 15 years of age, a 
national post-campaign vaccination coverage survey was conducted. In conjunction with this 
survey, a nested serosurvey was conducted in Southern Province that involved collecting 
biospecimens from all members of households enrolled in the post-campaign vaccine coverage 
survey. Dried blood spots were collected by fingerprick for enrolled individuals (Hayford et al., 
2019). The WHO vaccination survey manual was used for the household-based survey design 
(World Health Organization, 2018b). Clusters were defined as administrative boundaries known 
as Supervisory Enumeration Area based on the most recent census conducted in 2010. Each 
cluster was selected to enroll 12 children who were eligible at the time of the vaccination 
campaign. Only 16 of the 26 clusters selected for the coverage survey in Southern Province 
participated in the serosurvey for logistical reasons.   
 
Cost data 
The financial costs were estimated using ingredients-based costing within activities 
approach, except for missing data, for which gross expenditure costing was used (Levin & 
McEwan, 2001; McEwan, 2012). The cost analysis was performed from the government-funded 
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healthcare perspective, where a non-government organization was hired as the implementing 
partner. We did not consider participant costs. Cost data were captured in local currency and 
converted into US dollars using the annual exchange rate in 2016 (USD $1=10.3 Kwacha) 
(World Bank, 2018). We considered a two-month time horizon for implementation of the 
serosurvey, from planning to laboratory processing. Weighting for incremental costs and 
discounting were not performed. Serosurvey cost data were obtained through document review 
of the budget and program records (such as purchase orders and contracts) and interviewing 
administrative personnel. When there was a difference between the budget and reported 
expenditure, reported expenditure was used to more accurately reflect the serosurvey as it was 
implemented rather than designed (McEwan, 2012).  
 
Serosurvey cost estimation 
A costing framework for integrated disease surveillance was adapted to capture the 
categories of implementation inputs across serosurvey functions (Figure 7). Serosurvey functions 
captured the phase of implementation from planning to data and biospecimen collection in the 
field and laboratory testing. Cross-cutting items such as communication, supervision, and data 
management were placed in a separate category of coordination, as they spanned serosurvey 
functions. The framework was compared with Demographic Health Services and vaccination 
coverage survey budgets to ensure all costs were captured (Keogh, 2005). For each category, we 
identified the proportion of costs attributed to a traditional vaccination coverage survey and those 
that were specific to the serosurvey. Costs were also stratified by whether they varied at the 





We recorded the number of workers required for each activity. Long-term personnel who 
temporarily supported the serosurvey were allocated the time they spent doing serosurvey 
activities, including benefits. Personnel who were contracted specifically for the serosurvey had 
all their time included. We also included fees of consultants who supported specific services 
such as training. We apportioned total personnel costs to serosurvey activities based on the ratio 
of time spent doing serosurvey-specific activities (e.g., blood collection) compared to general 
survey activities (e.g., mapping). For the base case, one team was assumed to complete the 
serosurvey in one cluster within three days. The team consisted of a supervisor, phlebotomist, 
and three data collectors. 
Transportation 
No vehicles were purchased for the serosurvey; however, existing vehicles charged 
vehicle-use and driver time. Some vehicles were also rented at a fixed per day cost for vehicle 
use and driver time. Most transportation cost was allocated to general survey activities. Only 
biospecimen collection trips were included in serosurvey-specific costs. Each team was assigned 
one vehicle to implement field activities for the serosurvey. 
Field consumables 
Field consumables included the cost of any items required during data and biospecimen 
collection and was stratified by items required for general survey implementation, such as pens, 
and serosurvey-specific items, such as biospecimen collection kits (e.g. lancets, cotton, gloves). 
General survey items typically were calculated per cluster as they were team-level costs. 





Because social mobilization for the post-campaign vaccine coverage survey was done as 
part of the vaccination campaign, all additional social mobilization efforts were calculated as 
serosurvey-specific costs. This included stipends for community health workers to accompany 
the teams in the field during data collection, radio ads, and meetings and phone calls with health 
facility staff to notify them that a serosurvey was being conducted in their area. 
Laboratory supplies 
Laboratory costs were calculated based on the cost of supplies and consumable materials 
(e.g. test kits, gloves, tubes). The cost of bench space was based on the time required for 
laboratory testing. We assumed a laboratory providing services for a serosurveys has the 
equipment to conduct enzyme immunoassays using commercial kits; therefore we did not 
account for equipment or cost of maintenance. It was assumed that 15% of biospecimens would 
be retested in the base case to account for quality assurance and quality control, as well as 
retesting biospecimens with equivocal results and biospecimens with results above the upper 
limit of detection for a commercial measles and rubella IgG enzyme immunoassay kit. 
Capital items and overhead 
Because we costed a single serosurvey, the only capital items purchased specifically for 
the serosurvey were tablets for data entry. All other equipment was borrowed, and use-time was 
included in the cost. No overhead costs were included. 
 
Data analysis 
We used Microsoft Excel to compile and analyze the data. Using the number of clusters 
and participants included in the serosurvey, we calculated the average per cluster and per 
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participant costs, as well as the marginal cost per cluster and participant.  Estimated costs were 
then stratified by serosurvey activity.  Inputs were also stratified by whether they were general to 
surveys or attributable specifically to serosurveys. One-way sensitivity analyses were conducted 
for personnel and time spent on various activities. 
Marginal costs for an additional cluster were calculated based on social mobilization, 
personnel, team materials and transportation required to include a cluster in the survey. This 
included one day for enumeration, mapping, and social mobilization preparatory activities 
required at the cluster. Marginal costs for an additional participant in an existing cluster included 
consumables for biospecimen collection and laboratory testing as well as additional time for 
personnel and transport. 
These marginal costs were used to estimate the cost of conducting a similar survey under 
different assumptions. Sample sizes were estimated using the Expanded Program on 
Immunization (EPI) cluster survey methodology for varying population immunity levels, 
precision, and design effects (World Health Organization, 2018b). Precision around the point 
estimates were modified for the sample sizes by changing both number of clusters and number of 
participants per cluster. These sample sizes were then costed using the marginal costs per 
participant and clusters to estimate the cost of conducting these serosurveys at varying precision 
and assumed population immunity levels. We assumed similar underlying seroprevalence across 
clusters for these analyses. 
Results 
Biospecimens were collected from 658 individuals in 16 clusters by four teams 
comprised of 5 members each (supervisor, interviewers, and blood collector). Each team took 
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approximately 3 days to complete each cluster. One and half weeks were calculated for training 
and piloting, and 3 weeks were required for laboratory testing. With these assumptions, we 
estimated that it cost US $68,558 to collect biospecimens in a household vaccination coverage 
survey in Southern Province, Zambia.  This resulted in a cost of $4,285 per average cluster and 
$104 per average participant sampled.  
Personnel costs were the largest contributing input to overall serosurvey costs (51%), 
transportation was second (23%), and field consumables was third (9%) (Figure 8). A breakdown 
of the cost by serosurvey activity is presented in Table 9. Data collection in the field accounted 
for almost one third of the total serosurvey cost (32%), followed by survey preparation (25%) 
and biospecimen collection (20%). The overall added cost of collecting and testing a 
biospecimen as part of the survey was $24,601 (36%). In terms of costs attributable exclusively 
to serosurveys, personnel costs were also the largest input (34%) due to added time in the field 
and laboratory personnel, followed by laboratory supplies (26%) and social mobilization (18%). 
By combining the serosurvey with the vaccination coverage survey, there was a savings of 
$43,957, the cost of completing just the vaccination coverage survey. 
We estimated that the marginal cost of including an additional cluster was $1,620, and 
the marginal cost of adding a participant within an existing cluster was $30. For these, 46% of 
the cost to add a cluster and 64% of the cost to add a participant were attributable to serosurvey-
specific costs. In the serosurvey, all members of the household including both adults and children 
were enrolled, whereas only children were included in the vaccination coverage survey. 
Incorporating more than one child per household, comprising an additional 235 children, added 
$7,030 to the serosurvey cost; including 219 adults in the serosurvey cost an additional $6,552.  
75 
 
Few participants were seronegative for measles or rubella, as the serosurvey was 
conducted after an immunization campaign. Given that 33 participants were measles 
seronegative, the average cost per seronegative identified was $2,077. There were 18 participants 
seronegative for rubella, resulting in an average cost of $3,809 per seronegative identified. 
Accounting for both measles and rubella seronegatives, it cost $1,344 per susceptible identified. 
Sensitivity analyses show that varying time for field work and number of team members 
had the largest impact on serosurvey cost, as this also affected field work time (Figure 9). These 
factors impacted the data collection phase, which accounted for most of the study’s costs. 
However, none of the sensitivity analyses changed the cost by more than 8%. 
 
Costs associated with varying sampling design 
Additional sensitivity analyses were conducted to evaluate how varying the sampling 
design of the serosurvey affected cost. Our base case of the nested serosurvey used to estimate 
costs had an average of 43 participants enrolled per cluster (SD=17). The intraclass correlation 
was 0.026 for measles with a mean seroprevalence of 96.5% (SD=5.1) and 0.005 for rubella, 
with a mean seroprevalence of 95% (SD=6.0). The sample size conditions for the nested 
serosurvey assumed 85% estimated population immunity with +/-7% precision and a design 
effect of 1.4, which would have required 16 clusters with 12 participants per cluster. Varying 
sampling parameters had differential effects on the cost of a serosurvey. 
Estimating seroprevalence in settings where it is assumed to be high has lower associated 
costs than settings with lower seroprevalence due to the decreased sample size required to obtain 
a point estimate with a specified precision, and thus the range of costs is smaller (Figure 10).  
The design effect (DEF) can also have substantial implications for cost, with a higher DEF 
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having a higher cost. For example, 85% population immunity with 5% precision and 10 clusters 
can cost $76,684 when the DEF=1.4 or $99,709 when DEF=2.0 due to the increased number of 
participants needed with higher design effect (Figure 11).   
While the effective sample size for improving precision around a point estimate will 
always increase, how the cost of the larger sample size increases depends on the marginal cluster 
cost and marginal participant cost. In our nested serosurvey, the cost ratio (marginal cluster 
cost/marginal participant cost=$1,620/$30) was 54, reflective of a much higher cost to add a 
cluster of average size compared to adding an additional participant within an existing cluster 
(Kish, 1965). Our average cluster size was 42 participants. Assuming 85% seroprevalence and 
that all clusters have similar seroprevalence, improving from +/-10% precision to +/-5% by 
keeping the number of participants the same and adding clusters resulted in a cost increase of 
$33,636 (Table 10).  Whereas improving the same precision by maintaining the number of 
clusters and adding participants within a cluster, resulted in a cost increase of only $6,225. 
(Table 11). Figure 12 demonstrates that for the 85% estimated population immunity and 5% 
precision, the total number of participants required would be 275, which can be achieved with 
varying combinations of number of geographic clusters and participants at varying cost, 
assuming underlying immunity is similar across clusters. Using this figure, if you had $60,000 to 
conduct a serosurvey, you would be limited to doing so in 17 or fewer clusters. 
Discussion 
Economic evaluations of public health surveillance systems have used various 
methodologies, making it difficult to compare across settings (Herida, Dervaux, & Desenclos, 
2016). To compare serosurvey costs across settings, we developed a framework for serological 
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surveillance and used it to estimate the costs of a nested serosurvey in Southern Province, 
Zambia. Standardized categories permit cross-country comparisons and could be used as a model 
for other countries considering serological surveillance.  
Few costing studies of serological surveillance have been conducted, and to our 
knowledge, none have been done for measles and rubella serosurveys. By nesting this serosurvey 
within a planned post-campaign vaccine coverage survey, costs for planning, personnel, 
mapping, enumeration, and transportation were not borne by the serosurvey. WHO estimated 
that 60-70% of a serosurvey budget is laboratory-related supplies for blood collection, storage, 
transport, processing, and testing kits (World Health Organization, 2015). We estimated that the 
added time for biospecimen collection in the field and laboratory-related supplies were only 36% 
of the overall serosurvey budget. This could be due to the limited serosurvey transportation cost, 
as we did not have vehicles allocated specifically for biospecimen transport. Another potential 
explanation for these differences could be the biological specimen type. Since we used 
fingerpick blood collection, this may have reduced the costs of biospecimen collection, as it does 
not require personnel skilled in venous blood draw. Collecting biospecimens as dried blood spots 
eliminated the need for a reverse cold chain and time-sensitive transportation to the laboratory. 
Although the MR vaccination campaign targeted children younger than 15 years of age, 
monitoring seroprevalence in adults is important because as measles and rubella virus circulation 
diminishes, fewer people are immunized through natural infection in childhood and will be at 
risk of acquiring disease as adults. This is of particular concern for women of childbearing age, 
as it could result in increased congenital rubella syndrome cases (Lessler & Metcalf, 2013). In 
this serosurvey, lower rubella seroprevalence (88%) was identified in women 16 to younger than 
30 years of age, the age group in which protection from rubella is critical to prevent CRS. It cost 
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an additional $6,552 to include the 219 adults in households were children were already being 
enrolled. The serosurvey revealed immunity gaps among young adults not eligible for the 
campaign, gaps which would not have been identified through the vaccination coverage survey 
alone. This adult population can be monitored through serological surveillance without a 
substantial increase in funds required. 
Understanding the factors that have the greatest effect on serosurvey cost can be used to 
minimize these costs. Other household surveys have noted that cost of survey implementation in 
sub-Saharan Africa is often higher than in other regions due to high personnel costs (Kilic, 
2017). An EPI costing study in Zambia also identified personnel and travel as the highest 
implementation costs for routine immunization (Schutte et al., 2015). Similarly, our survey 
identified personnel and transportation as the highest cost inputs; however, we were able to save 
$26,539 in personnel and $13,410 in transportation by nesting within the post-campaign vaccine 
coverage survey.  
Using an existing biorepository rather than collecting new biospecimens could result in 
cost-savings in the areas of data collection and biospecimen collection, which together account 
for more than half the cost of the serosurvey.  Other ways to reduce costs include limiting 
training time by using experienced data collectors and improving data collection tools to 
minimize time in the field. 
As new technology continues to develop such as point-of-care technology to detect 
antibodies, laboratory costs could be affected. These technologies might be more expensive than 
current laboratory methodologies, but they may not require specimen transportation and could be 
done by non-laboratory personnel which could decrease costs (Vojnov et al., 2019). The use of 
multiplex bead arrays to detect multiple antigens from the same biospecimen, could make 
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serosurveys more cost-effective by providing information on multiple diseases in less time 
without requiring additional biospecimen collection (Itell et al., 2018). 
The cost for identifying someone who is seronegative was high in this population because 
of the high seroprevalence and thus few seronegative individuals. The cost per seronegative 
individual will vary across settings and would be lower where seroprevalence is lower. By 
contrast, it is cheapest to conduct a serosurvey, with the objective of obtaining a seroprevalence 
estimate, in settings where seroprevalence is higher because of the decreased sample size 
required. The objective of the serosurvey in this case is important to understand. For example, if 
a serosurvey is being conducted to verify elimination status, or confirm the effectiveness of a 
vaccination campaign, high seroprevalence would be expected. Similarly, if an area has high 
routine immunization coverage, high seroprevalence would be expected. If a country were 
prioritizing areas for vaccination campaigns, a serosurvey could be conducted in the area to 
confirm high seroprevalence, allowing the country to consider not vaccinating in that area, but 
rather focus on areas where seroprevalence is low. On the other hand, conducting a serosurvey in 
areas with low expected seroprevalence would more expensive because of an increased sample 
size needed, but would result in the identification of more people who are seronegative who 
could be targeted for vaccination campaigns. 
As demonstrated by the sample size estimates, the cost of increasing precision varies 
greatly depending on design effect, estimated population immunity, and number of clusters. 
Achieving additional precision by adding participants within clusters had less of an impact on 
cost, as the cost of including an additional cluster far outweighs the cost of including an 
additional participant within that cluster. However, adding additional participants in a 
homogenous cluster does not provide additional information. Careful consideration of when 
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inclusion of another cluster is needed will depend on the heterogeneity between clusters, and 




Since the data sources were requested a year after the study was completed, the 
uncertainty in cost estimates may vary based on quality of record keeping (McEwan, 2012). 
Because this was a one-time activity, new personnel were not hired, but rather contracted for 
their time. If this were to be an ongoing activity, hiring additional personnel or allocating a 
proportion of existing personnel time would be needed. Transportation costs were based on per 
day use rather than actual mileage covered.  We were not able to estimate the marginal cost per 
household due to the format of the costing data and the variable number of people included per 
household; therefore, estimates were based on participant costs. These costing estimates were for 
the actual number of participants enrolled and may not account for additional time required if 
conducting a serosurvey in a setting with high refusal rates or non-response that would require 
additional time spent on enrollment.  
Similarly, sample size estimates demonstrate the relationship between precision around 
an estimate and cost, but they do not consider the potential for bias. The cost of conducting the 
serosurvey decreases with fewer clusters but sampling too few clusters could increase the 
potential for bias. Our intraclass correlation for the base case used to cost the study was low, but 
in a setting with higher intraclass correlation, there would be a higher design effect. The 
implications for the number of clusters to include would be important to provide an accurate 
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seroprevalence cost estimate. Balancing the desire to lower cost and the precision of the 
seroprevalence estimate could be simulated using varying seroprevalence estimates per cluster. 
Conclusion 
Adding serological specimen collection to a planned vaccination coverage survey in 
Southern Province, Zambia provided a more direct measurement of population immunity, while 
increasing the cost by approximately one-third. Vaccination coverage can provide an estimate of 
how many children were vaccinated but does not consider non-response to vaccination or natural 
infection, therefore not providing true population immunity. Instead, serosurveys can directly 
measure population immunity and be done efficiently by nesting the serosurvey within a 
vaccination coverage survey to save costs. Strategies in cluster survey design methodology can 
help identify ways to minimize costs. Future serosurveys could consider ways to leverage 




Tables and Figures 
 
Table 9. Costs per phase of serosurvey implementation in Southern province, Zambia 
Serosurvey phase Cost (2016 USD) Percentage of total cost 
Survey preparation $        16,813 25% 
Data collection $        22,062 32% 
Biospecimen collection $        13,875 20% 
Laboratory testing $        10,726 16% 
Coordination (Communication, 
Data management) $         5,081 7% 
TOTAL $        68,558 
 
Notes: Phases of the serosurvey correspond to Figure 7. Percentages sum to 100%. All costs in 
2016 USD. 
 











+/-10 11 12  $ 44,724  
+/-7 21 12  $ 64,510  
+/-5 41 12  $104,082  
75 
+/-10 9 12  $ 40,767  
+/-7 18 12  $ 58,574  
+/-5 34 12  $ 90,231  
85 
+/-10 6 12  $ 34,831  
+/-7 12 12  $ 46,703  
+/-5 23 12  $ 68,467  
95 +/-5 9 12  $ 40,767  
Notes: Sample sizes are calculated for corresponding assumed seroprevalence estimate, margin 
of error, number of clusters, and number of participants per cluster. Assumed DEF=1.4, 
alpha=0.05, and one participant per household. Total cost= base cost ($22,960) + number of 
clusters*marginal cluster cost ($1,620) + number of participants per cluster *number of clusters* 
marginal cluster cost ($30). All costs in 2016 USD. 
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+/-10 16 8  $     52,695  
+/-7 16 16  $     56,526  
+/-5 16 31  $     63,709  
75 
+/-10 16 7  $     52,216  
+/-7 16 13  $     55,089  
+/-5 16 26  $     61,315  
85 
+/-10 16 5  $     51,258  
+/-7 16 9  $     53,174  
+/-5 16 18  $     57,484  
95 +/-5 16 7  $     52,216  
Notes: Sample sizes are calculated for corresponding assumed seroprevalence estimate, margin 
of error, number of clusters, and number of participants per cluster. Assumed DEF=1.4, 
alpha=0.05, and one participant per household. Total cost= base cost ($22,960) + number of 
clusters*marginal cluster cost ($1,620) + number of participants per cluster *number of clusters* 




Figure 7. Framework for estimating serosurvey costs 
 
 
Notes: Framework was adapted from integrated disease surveillance and updated to capture serosurvey costs. Phase of study includes 




























































Figure 8. Costs for the post-campaign vaccine coverage survey and serosurvey in Southern Province, Zambia by input category 
 
 
Notes: Costs captured for each input category span across serosurvey activities. Dark blue represents costs that would be inherent in a 
vaccination coverage survey, while light blue represents the costs that are specifically attributable to a serosurvey due to blood 



















Figure 9. One-way sensitivity analyses of costs varying serosurvey parameters 
 
   
Notes: One-way sensitivity analysis represents how varying parameters increased (changed the total serosurvey cost from the base 
case of $68,558. Negative values (to the left) indicate lower cost than the base case, reflecting the lower end of the ranges, and the 
positive values (to the right) indicate higher cost than the base case, reflecting the higher end of the ranges. The number of team 
members varied from 2 to 6, the time for field work varied from 10 to 15 days, the time for training varied from 3 to 8 days, and the 
time for planning varied from 5 to 10 days. The percentage of specimens requiring retesting varied from 5 to 25% and the time for 
laboratory testing varied from 13 to 23 days. All costs are in 2016 USD. 
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Figure 10. Sample size costing with varying estimates of seroprevalence at +/-5% precision 
 
  
Notes: The number of participants per cluster, shown on the x-axis, determines the number of clusters required to maintain +/-5% 
precision (number of clusters not depicted). The design effect is assumed to be 1.4. Total cost= base cost ($22,960) + number of 
clusters*marginal cluster cost ($1,620) + number of participants per cluster *number of clusters* marginal cluster cost ($30). All costs 




Figure 11. Sample size costing with varying precision at 85% seroprevalence with design effects of 1.4 and 2.0 
 
 
Notes: Assumed estimated seroprevalence remains constant at 85%. The number of participants per cluster, shown on the x-axis, 
determines the number of clusters required to maintain +/-5% precision (number of clusters not depicted). The design effect is 
assumed to be 1.4 or 2.0. Total cost= base cost ($22,960) + number of clusters*marginal cluster cost ($1,620) + number of participants 










Notes: Assumed estimated seroprevalence remains constant at 85%. The number of participants per cluster, shown on the x-axis varies 
along with the number of clusters required to maintain +/-5% precision. Size of bubbles and number to the right of bubbles represent 
the number of clusters. The design effect is assumed to be 1.4, and alpha=0.05. Total cost= base cost ($22,960) + number of 
clusters*marginal cluster cost ($1,620) + number of participants per cluster *number of clusters* marginal cluster cost ($30). All costs 
in 2016 USD.  
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Paper 3- Comparing two serosurveys in 
Southern Province, Zambia to assess the 
impact of a measles and rubella vaccination 
campaign on seroprevalence  
Abstract 
Introduction: In September 2016, a national catch-up measles and rubella (MR) vaccination 
campaign was conducted in Zambia and was the first introduction of rubella-containing vaccine 
in the public sector. Given that approximately 95% population immunity is needed to interrupt 
measles virus transmission, a serosurvey can determine whether this threshold is met. To 
evaluate the impact of the vaccination campaign on population immunity, we compared the 
results of measles and rubella serosurveys conducted before and after the MR vaccination 
campaign to observe changes in seroprevalence in Southern Province, Zambia. Reported 
administrative first-dose measles coverage was 110% among children 12-24 months of age and 
second-dose measles coverage was 59% among children 24 months of age in 2016. 
Methods: In early 2016, prior to the MR campaign, the Zambia Population HIV Impact 
Assessment was conducted as a cross-sectional household survey to estimate HIV incidence and 
prevalence. This study collected venous blood specimens from participants younger than 50 
years of age. A sub-sample of 1,105 specimens from Southern Province were selected for 
measles and rubella testing based on HIV status, age, and cluster. In November 2016, a 
serosurvey to assess measles and rubella seroprevalence was conducted as part of a post-
campaign vaccination coverage survey. This study collected dried blood spots from 543 
participants 9 months to 49 years of age in 14 clusters. Specimens from these serosurveys were 
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tested for measles and rubella IgG antibodies using two commercially available enzyme-linked 
immunoassays (EIAs). Results were weighted to account for survey design, non-response, and 
adjusted for population age distribution. The two serosurveys were assessed for comparability. 
Results: The overall seroprevalence among people under 50 years of age increased from 64.2% 
(95% CI: 59.3-68.8) before the MR vaccination campaign to 95.5% (95% CI: 93.6-97.5) after the 
campaign for measles, and rubella seroprevalence increased from 72.2% (95% CI: 67.6-76.3) to 
95.9% (95% CI: 92.2-99.6). After the vaccination campaign, seroprevalence to measles increased 
from 57.2% (95% CI: 51.9-62.4) to 96.4% (95% CI: 91.7-98.5) among children younger than 15 
years of age, and rubella seroprevalence increased from 51.3% (95% CI: 45.6-57.0) to 98.3% 
(95% CI: 95.5-99.4). In the pre-campaign serosurvey, age was associated with seroprevalence for 
both measles and rubella. Measles seropositivity was higher among HIV uninfected children 
under 15 years of age (57.5%, 95% CI: 52.1-62.7) than among HIV infected children (25.2%, 
95%CI: 5.9-64.4).  By contrast, seroprevalence to rubella was higher among HIV infected 
children under 15 years of age (100%) than among HIV uninfected children (50.9%, 95% CI: 
45.1-56.6) in the pre-campaign serosurvey.  
Conclusions:  A comparison of the two serosurveys showed significant increases in 
seroprevalence from the pre-campaign to the post-campaign for both measles and rubella, 
highlighting the impact of the mass vaccination campaign in 2016. Despite high routine 
vaccination coverage, the pre-campaign survey found low measles seroprevalence in Southern 
Province, Zambia. The pre-campaign serosurvey also demonstrates differential seroprevalence 
rates among HIV infected children and the potential need for additional vaccination against 
measles. The serosurvey conducted after the MR vaccination campaign found high 
seroprevalence to both measles and rubella viruses, and there was no association of 
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seroprevalence with age, demonstrating how vaccination campaigns can close population 
immunity gaps. 
Introduction 
Measles is a highly infectious disease that was estimated to be one of the five major 
causes of death in children under 5 years of age in Zambia before the availability of vaccine 
(CDC, 2001). Thanks to measles vaccination, measles deaths dropped 84% from 550,100 in 
2000 to 89,780 in 2016 worldwide, with Africa accounting for 44% of measles deaths (Dabbagh 
et al., 2018; World Health Organization, 2012). 
Although not a major cause of childhood mortality, rubella is a major cause of congenital 
defects, estimated to affect 105,391 infants in 2010, with 37% of cases in Africa (Vynnycky et 
al., 2016). The most effective way to prevent congenital rubella syndrome (CRS) is through 
widespread immunization, ensuring that women of childbearing age are protected against 
rubella. 
The African Region established a goal of measles elimination by the end of 2020. The 
primary component of elimination strategy is to achieve high population immunity by providing 
high vaccination coverage with two doses of measles and rubella-containing vaccines (World 
Health Organization, 2012). 
Measles vaccination was introduced into the routine immunization program in Zambia in 
1983; however, widespread outbreaks continued with 26,072 suspected cases of measles reported 
annually from 1994-2003 (CDC, 2005). To improve population immunity to measles virus, 
vaccination campaigns were conducted in 2003, 2007, 2010, and 2012. However, there was still 
a nationwide measles outbreak in 2010-2011 with up to 37,582 cases reported (Mpabalwani ME, 
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2013).  Zambia introduced a second dose of measles vaccine (MCV2) in 2013, but coverage was 
only 56% in 2016 (Zambian Ministry of Health, 2019b). 
In September 2016, a national catch-up measles and rubella (MR) vaccination campaign 
was conducted in Zambia targeting all children 9 months to younger than 15 years of age. This 
campaign was the first introduction of rubella-containing vaccine (RCV) in the public sector, and 
RCV was included in the routine immunization program (Masresha et al., 2017). 
The impact of vaccination campaigns can be assessed in multiple ways, including 
vaccination coverage achieved by the campaign, the number of zero-dose children vaccinated, 
and the proportion of children receiving at least one or two vaccine doses. However, these do not 
account for potential vaccine failures. Tracking the number of cases reported before and after a 
campaign can also be used to evaluate campaign effectiveness if surveillance is sufficiently 
sensitive to identify cases. Zambia’s fever rash surveillance struggles to meet targets for 
indicators of a sensitive surveillance system. Monitoring cases is also a lagging indicator, as it 
identifies population immunity gaps that existed at time of measles virus transmission. 
Serological surveillance can provide a more direct measurement of changes in population 
immunity before and after a vaccination campaign. Given that approximately 95% population 
immunity is needed to interrupt measles virus transmission, a serosurvey can determine whether 
this threshold is met. To evaluate the impact of the vaccination campaign on population 
immunity, we compared serosurveys conducted in Southern Province, Zambia before and after 
the 2016 MR vaccination campaign to observe changes in population immunity. To determine 
the comparability of the two serosurveys, we evaluated the impact of different sampling 






This study was conducted in Southern Province, the third most populous province in 
Zambia with 1.9 million inhabitants across 13 districts in 2016 (Zambia Central Statistical 
Office, 2013). The population age structure is expanding with 48% of the population under 15 
years of age and a total fertility rate of 5.7. The infant mortality rate remains high at 62 per 1,000 
live births, and life expectancy at birth is 59 years of age.  Southern Province has the fourth 
highest HIV prevalence in Zambia, estimated at 13% in 2016 (Columbia University, 2016). 
Reported administrative first-dose measles coverage was 110% among children 12-24 months of 
age and second-dose measles coverage was 59% among children 24 months of age in 2016 
(Zambian Ministry of Health, 2019b). 
 
Data and biospecimen collection 
Specimens were collected within two studies conducted in Southern Province in 2016. 
The first study collected specimens from participants before the MR vaccination campaign, and 
the second collected specimens 3 months after the campaign. Table 12 compares the study 
designs for these two serosurveys. 
All studies were approved by the Institutional Review Board at Johns Hopkins 
Bloomberg School of Public Health and the Zambian Ministry of Health. The pre-vaccination 
campaign was approved by the National Regulatory Authority, and the post-vaccination 





Pre-vaccination campaign data collection 
In early 2016, the Zambia Population HIV Impact Assessment (ZamPHIA), was 
conducted as a cross-sectional community survey to estimate HIV incidence and prevalence. The 
survey design was a two-stage cluster survey methodology with clusters selected from the 2010 
census with probability of selection proportional to estimated size. Within each cluster, 
households were listed, and a random sample of households within each cluster were selected 
based on a computer algorithm. This study then collected survey data and venous blood 
specimens from adults 15 to 49 years of age in every household selected. In half of the 
households selected, children younger than 15 years of age were also included, with dried blood 
spots collected from finger prick for children 6-23 months of age and from heel prick for 
children under 6 months of age (Ministry of Health, Zambia, 2017). This study was powered to 
estimate provincial HIV incidence rates by selecting enumeration areas in each province. This 
study reported 11% households refused to provide blood specimens, and only 68% of eligible 
children participated (Columbia University, 2016).  HIV home-based testing and counseling 
were conducted. Individuals with nonreactive result on the screening test were classified as HIV 
uninfected. Those with a reactive test result underwent confirmatory testing using Uni-Gold, and 
if reactive again were classified as HIV infected. Individuals with reactive screening and 
nonreactive confirmatory tests were classified as indeterminate and counseled to seek a repeat 
test in 4 weeks, according to national guidelines (Columbia University, 2016). After specimens 
were transported to the central laboratory and completed any additional HIV testing, residual 
plasma and dried blood spots study were frozen in a biorepository at -70°C in Ndola, Zambia. 
 Residual plasma and DBS samples from this study were tested for anti-measles virus and 
anti-rubella virus IgG antibodies. Of the 2,648 specimens collected in Southern Province, 1,105 
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were selected for testing to estimate age-specific seroprevalence to measles and rubella with 10% 
precision. Specimens were selected based on HIV status, cluster representation, and age. All HIV 
infected participants and clusters with fewer than 10 participants were selected for testing. To 
ensure sufficient sample size for age-specific seroprevalence estimates, participants <5, 5-9, and 
10-14 years of age were selected to represent 22% of the subsample in each category, and 
participants 15-19 and 20-49 years were selected to represent 17% of the subsample in each 
category. Additionally, at least one respondent from every cluster was included. Serological 
results were linked to clinical and demographic variables in the ZamPHIA database but data on 
measles vaccination status were not collected. 
 
Post-vaccination campaign data collection 
In November 2016, a serosurvey to assess measles and rubella seroprevalence was 
conducted as part of a post-campaign vaccination coverage survey conducted by the Ministry of 
Health. The nested serological survey used the same sampling strategy as the post-campaign 
vaccination coverage survey, a two-stage cluster survey with the clusters selected from the 2010 
census with probability of selection proportional to estimated size. Twenty-six clusters were 
selected in Southern Province. Within each cluster, households with children in the post-
campaign vaccination coverage survey target age group (9 months to less than 15 years) were 
eligible for enrollment.  Households in each cluster were listed and designated as either (1) 
having all children vaccinated or (2) having at least one child unvaccinated. A total of 12 
households per cluster were enrolled, with a stratified allocation ratio of 2:1 vaccinated to 
unvaccinated households to permit analysis of reasons for not being vaccinated. If there were not 
sufficient unvaccinated households, vaccinated households were included instead. 
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The nested serosurvey was designed to estimate seroprevalence within +/-7% for 
prespecified age groups (<5, 5-9, 10-14, and 15 years of age and older). This serosurvey was 
nested in 14 of the 26 clusters selected for Southern Province. All households included in the 
vaccination coverage survey were eligible for the nested serosurvey. Whereas the vaccination 
coverage survey included only children eligible for the campaign, the nested serosurvey included 
all members 9 months of age and older who were present at the time of the serosurvey. Dried 
blood spots were collected by fingerpick from all participants, placed in plastic storage bags with 
a desiccant, and kept at room temperature for 1-3 days until transfer to the laboratory for long-
term storage at -20° C (Hayford et al., 2019). Information on measles vaccination history, 
including routine measles vaccination and MR vaccination during the campaign, were collected 




For the pre-campaign serosurvey, plasma specimens were thawed overnight at 4°C. 
Specimens were processed as recommended by the manufacturer and tested for anti-measles 
virus IgG and anti-rubella virus IgG antibodies using indirect enzyme immunoassays 
(Euroimmun; Lübeck, Germany). Blood collected as DBS was eluted according to a protocol 
optimized for use with the Euroimmun assays. A quantitative antibody concentration was 
generated based on curves and manufacturer’s thresholds. Measles results were classified as 
positive (>275 mIU/mL), equivocal (>200 to <275 mIU/mL), or negative (<200 mIU/mL). 
Rubella results were classified as positive (>11 IU/mL), equivocal (>8 to <11 IU/mL), or 
negative (<8 IU/mL). Antibody concentrations for rubella were left-censored at the lower level 
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of detection (0.2 IU/mL) and right-censored at the upper level of detection (assigned 5,001 IU/L 
for measles and 201 IU/mL for rubella). Values above the upper limit of detection were not 
diluted and retested. Equivocal results were retested and, if equivocal again, were categorized as 
positive for analyses. Quality control and quality assurance procedures are detailed in Appendix 
5. A subset of 88 participants that had both DBS and plasma specimens were tested to assess 
concordance between DBS and plasma. Since these found 85% qualitative concordance for 
measles and 100% for rubella, we opted not to adjust the DBS specimens. Testing was split 
between the National Virology Lab at the University Teaching Hospital in Lusaka and the 
Tropical Disease Research Center in Ndola. Testing was conducted from April to October 2019 
with near-real time data management and analysis from Johns Hopkins University. 
For the post-campaign serosurvey, serum eluted from DBS were tested for IgG antibodies 
to measles and rubella viruses with indirect enzyme immunoassays (Enzygnost; Siemens, 
Munich, Germany) at Macha Research Trust. The circumference of each DBS was measured, cut 
with sterilized scissors, and serum was eluted with 250 µL of buffer as described in an active 
elution protocol developed at the Centers for Disease Control and Prevention (Mercader, 
Featherstone, & Bellini, 2006). Fifty microliters of eluted sample were transferred to precoated 
96-well plates and the manufacturer’s protocol was followed to perform the EIA. The optical 
density (OD) was read at 450 nm using a BioTek ELx800 microplate reader (BioTek 
Instruments, Winooski, VT). Corrected optical density (cOD) differences were calculated based 
on differences in OD values for the antigen and control wells, the mean of positive and negative 
controls, and lot-specific parameters, as specified by the manufacturer. Specimens were 
classified as positive (>0.2 cOD), equivocal (0.1 – 0.2 cOD), or negative (<0.1 cOD); this would 
be approximately equal to 150 mIU/mL as the upper cut-off for negatives. For samples with cOD 
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>0.1 and OD<2.5, measles (mIU/mL) and rubella (IU/mL) antibody concentrations were 
calculated according to the manufacturer protocol. Equivocal results were re-tested and, if 
equivocal again, were categorized as positive for analyses. Adjustments were made to the DBS 
results to account for volume, spot size and diagnostic accuracy of DBS compared to a subset of 
serum (Hayford et al., 2018). 
Euroimmun reports 100% sensitivity and 100% specificity for measles IgG antibodies 
and Siemens reports 99.6% sensitivity and 100% specificity in the product inserts. Euroimmun 
reports 99.6% sensitivity and 100% specificity to rubella IgG, compared to Siemens having 
100% sensitivity and 98.5% specificity. A head-to-head comparison of Euroimmun and Siemens 
rubella kits found 96.3% agreement for IgG in plasma (Hardelid et al., 2008). There is no 
reported head-to-head comparison for the measles kits. 
 
Data analysis 
Results were weighted to account for the inverse probability of selection, non-response, 
and post-stratification adjustments based on each survey design. The pre-campaign serosurvey 
used individual-level weights based on selection probability (by age, HIV status, and cluster), 
non-response based on non-availability of specimens in the biorepository, and post-stratification 
adjustment to the Southern Province population age and sex structure. For the post-campaign 
serosurvey, household-level weights were calculated based on selection probability by 
vaccination status and cluster, non-response based on number of households that refused to 
participate despite being included in the household listing in the clusters, and post-stratification 
to account for any changes in the sampling frame predictions from the 2010 census predictions 
(Zambian Ministry of Health, 2017). Given the differential selection criteria, Figure 13 depicts 
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factors associated with inclusion in each serosurvey and how they were adjusted to calculate the 
overall seroprevalence estimates. 
Categorical variables and age-specific seroprevalence estimates were compared using 
Rao-Scott chi-square tests. Penalized regression spline was used to model age-specific 
seroprevalence. Overall provincial seroprevalence estimates were calculated using direct age and 
sex adjustment based on 2016 population estimates from Zambian Central Statistics Office. This 
involved applying the proportion seropositive in each age and sex category to the standard 
population estimates from Southern Province to provide the expected number of seropositive 
people for each age and sex group based on a common population distribution. Summing the 
total number of seropositive people in the standard population provides the adjusted provincial 
seroprevalence (Tripepi, Jager, Dekker, & Zoccali, 2010). 
Results 
From the pre-campaign serosurvey, 1,105 specimens were tested for measles and rubella 
IgG antibodies, and 543 specimens were tested from the post-campaign serosurvey. The pre-
campaign serosurvey had more adults 15 years of age and older (49%) than the post survey 
(34%) (Table 13). Additionally, males were under-represented in the post-campaign serosurvey 
(45%). In the oldest age group (20-49 years), 49% of participants were male in the pre-campaign 
serosurvey, whereas only 25% were male in the post-campaign serosurvey.  In the pre-campaign 






Seroprevalence by age 
Measles seroprevalence prior to the vaccination campaign was 57.2% (95% CI: 51.9-
62.4) and increased to 96.4% (95% CI: 91.7-98.5) among participants younger than 15 years of 
age, those targeted during the campaign. Surprisingly, measles seroprevalence was higher among 
adults in the post-campaign serosurvey (93.3%, 95%CI: 84.5-97.3) compared to the pre-
campaign serosurvey (71.5%, 95% CI: 63.8-78.1). Figure 14 depicts the close in the 
seroprevalence gap from pre to post-campaign serosurvey by age among those under 30 years of 
age. Rubella seroprevalence increased from 51.3% (95%CI: 45.6-57.0) to 98.3% (95%CI: 95.5-
99.4) among children younger than 15 years of age after the vaccination campaign. Figure 12 
depicts the close in the seroprevalence gap from pre to post-campaign serosurvey by age among 
those under 15 years of age. Unlike measles, there was no increase in rubella seroprevalence 
among adult age groups after the MR vaccination campaign. 
While there was some variability in measles seroprevalence by age group, there were no 
statistically significant differences within either the pre or post-campaign serosurvey (Figure 15). 
By contrast, in the pre-vaccination campaign serosurvey rubella seroprevalence had a strong 
positive association with age (Figure 15). Rubella seroprevalence significantly increased in each 
age category in the pre-campaign serosurvey, from 23.9% (95% CI: 17.8-31.2) among children 
under five-years old to 96.2% (95% CI: 93.0-98.0) in adults 20-49 years of age. 
 
Seroprevalence by sex 
Given the selection bias by sex, we conducted a stratified analysis of seroprevalence by 
sex to see if this led to differences in seroprevalence. Although there were no statistically 
significant differences, measles seroprevalence in the pre-vaccination serosurvey was slightly 
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higher in females (65.8%, 95%CI: 58.8-72.1) than males (62.6%, 95%CI: 57.8-67.1) for measles, 
and rubella seroprevalence was higher in females (73.6%; 95%CI: 67.2-79.2) than males (70.7%; 
95%CI: 65.8-75.2).   
Similarly, we conducted a stratified analysis of seroprevalence by sex within age 
categories to see if there were differences. Although there were no statistically significant 
differences in sex, like the overall sex differences in the pre-campaign serosurvey, females had 
slightly higher measles seroprevalence than males in almost every age category (Figure 16).  
Similarly, females had slightly higher rubella seroprevalence among children under 10 years of 
age and adults 20-49 years old. (Figure 17). 
 
Differences in antibody concentrations 
Geometric mean concentration for measles increased among children under 15 years of 
age from 270 mIU/mL (95% CI: 254-287) before the campaign to 1642 mIU/mL (95% CI: 1507-
1788) after the campaign (Figure 18). The distribution of measles antibody concentrations shifts 
from a tight distribution peaking around the 200 mIU/mL cutoff in the pre-campaign serosurvey 
to a disperse distribution in the post serosurvey. The under 15-year-old participants shift to a 
peak around 2000 mIU/mL, consistent with seroconversion as well as boosting following 
vaccination. Among adults 15 years of age and older, geometric mean concentrations were 475 
mIU/mL (95% CI: 421-536) in the pre-campaign serosurvey and 1554 mIU/mL (95% CI: 1344-
1795) in the post-campaign serosurvey. Again, the distribution peak shifts from being around 
200 mIU/mL in the pre-campaign serosurvey to around 1,000 mIU/mL in the post-campaign 
serosurvey. Overall, 1.5% of specimens in the pre-campaign serosurvey and 8.3% of specimens 
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in the post-campaign serosurvey were above the upper limit of detection for measles. No measles 
specimens were below the lower limit of detection (8 mIU/mL). 
Geometric mean concentration for rubella increased among children under 15 years of 
age from 14 IU/mL (95% CI: 11-17) before the campaign to 153 IU/mL (95% CI: 145-161) after 
the campaign. Rubella antibody concentrations shifted from a bimodal distribution in the pre-
campaign serosurvey for those under 15 years of age, to skewed single peak at the upper limit of 
detection (200 IU/mL) in the post-campaign serosurvey (Figure 18). Among adults 15 years of 
age and older, geometric mean concentrations were 85 IU/mL (95% CI: 72-101) in the pre-
campaign serosurvey and 132 IU/mL (IQR: 120-145) in the post-campaign serosurvey. The 
distribution for adults 15 years of age and older are similar in the pre and post-campaign 
serosurveys, with a peak at the upper limit of detection. Overall, 46.4% of specimens in the pre-
campaign serosurvey and 52.1% of post-campaign specimens were above the upper limit of 
detection for rubella (200 IU/mL). In the pre-campaign, 12% of rubella specimens were below 
the lower limit of detection (0.3 IU/mL), and there were none in the post-campaign. 
 
Seroprevalence by HIV status in the pre-campaign serosurvey 
The pre-campaign serosurvey tested participants for HIV; therefore, we stratified 
seroprevalence by HIV infection status to see the effect of HIV on seroprevalence (Figure 19). 
Adults 15 years of age and older had higher HIV prevalence (13.8%, 95% CI: 8.8-20.9) than 
children under 15 years of age (0.9%, 95% CI: 0.5-1.7). Measles seropositivity was higher 
among HIV uninfected children under 15 years of age (57.5%, 95% CI: 52.1-62.7) than among 
HIV infected children (25.2%, 95%CI: 5.9-64.4). There were no differences in measles 
seropositivity by HIV infection status among adults 15 years of age and older. 
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On the other hand, rubella seroprevalence was significantly higher among HIV infected 
children under 15 years of age (100%) than among HIV uninfected children (50.9%, 95% CI: 
45.1-56.6) (Figure 19). The difference in rubella seropositivity by HIV infection status is no 
longer statistically significant among adults 15 years of age and older. 
 
Overall provincial seroprevalence estimates and effects of weighting and adjustments 
The overall seroprevalence for measles increased from 64.2% (95% CI: 59.3-68.8) before 
the MR vaccination campaign to 95.5% (95% CI: 93.6-97.5) after the campaign, after accounting 
for serosurvey designs and adjusting for different age and sex distributions in the serosurveys. 
Rubella seroprevalence increased from 72.2% (95% CI: 67.6-76.3) to 95.9% (95% CI: 92.2-99.6) 
after the MR vaccination campaign. Weighting by survey design tended to increase 
seroprevalence in the pre-campaign but did not substantially affect post-campaign 
seroprevalence (Table 14). Excluding HIV infected individuals from the pre-campaign 
serosurvey also did not change seroprevalence estimates. While all provincial estimates were 
similar regardless of weighting and adjustment, the weighted and age and sex adjusted estimates 
represent the most comparable populations. 
Discussion 
Measles and rubella seroprevalence significantly increased after the MR vaccination 
campaign in the target age children in Southern Province, Zambia. To determine whether this 
was a true increase in seroprevalence, it was first necessary to address the comparability of the 
two serosurveys. Seroprevalence to measles was lower than expected in the pre-campaign 
serosurvey in Southern Province, as they have reported high first-dose measles coverage for 
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many years, with 11 of 13 districts reporting coverage >95% in 2016, and introduced a second-
dose of measles vaccine in 2013 (Zambian Ministry of Health, 2019b). Participants 18 to 54 
months of age would have been eligible to receive 2 doses of routine measles containing vaccine, 
and participants 5-30 years of age would have had opportunities for vaccination during at least 
two past vaccination campaigns. In contrast, rubella seroprevalence from the pre-campaign 
serosurvey followed a typical age-specific seroprevalence curve prior to the introduction of 
rubella vaccine (Edmunds et al., 2000; Gomwalk & Ahmad, 1989; Winter et al., 2018). The 
serosurvey conducted after the vaccination campaign identified high seroprevalence for both 
measles and rubella. 
 
Differences in sampling and probability of inclusion 
These data were collected from two different cross-sectional studies that both had sub-
sampling within main studies and had different survey designs. However, both main studies used 
the same sampling frame of the 2010 census for Southern Province and selected clusters in the 
first stage of sampling based on probability proportional to size. At the second and third levels of 
sampling, the primary studies differed. The pre-campaign main study randomly selected 
households whereas the post-campaign serosurvey stratified household based on vaccination 
status. If more households with unvaccinated children were included than vaccinated, this could 
have artificially decreased seroprevalence in the post-campaign serosurvey, but this was 
accounted for in the selection probability weighting. The pre-campaign main study included 
adults 15 years of age and older in each household, but only children under 15 years of age in 
every other household. If the households with children included were less likely to be 
seropositive than those with children who were not included, this could bias the seroprevalence 
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estimate downwards. By contrast, the post-campaign main study focused on enrolling children 
15 years of age or younger. 
In terms of the sub-sampling from each of the main studies, the pre-campaign serosurvey 
maintained all clusters in the main study whereas the post-campaign serosurvey randomly 
selected 14 of 26 clusters. At the individual level, the pre-campaign serosurvey sub-sampled 
based on HIV status and age; whereas the post-campaign serosurvey included all participants 
present in the household at the time of data collection. At each of these levels, there could have 
been selection bias. To account for differential probabilities of inclusion, both serosurveys 
calculated probability of selection weights. These were multiplied by non-response weights to 
account for differential response rates. Weighting both serosurveys should have made them 
comparable to the original population of Southern Province used for the sampling frame.  
 
Differences in population distributions 
Both serosurveys included individuals 0-49 years of age; however, there were differential 
age distributions between the serosurveys. There were more older adults 20-49 years old 
included in the pre-campaign serosurvey than in the post-campaign serosurvey. Given the strong 
association between age and seroprevalence for both measles and rubella, older participants 
would be more likely to be seropositive. Therefore, comparing overall seroprevalence from the 
pre and post-campaign serosurveys can only be done if they are age-adjusted to a standard 
population. 
The increase in seroprevalence for children under 15 years of age was expected due to the 
vaccination campaign reaching 96.8% coverage (95% CI: 94.7-98.1) (Zambian Ministry of 
Health, 2017). In the 15-19-year age group, there was a slight spillover effect with six participant 
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15 years of age at the time of the campaign reporting having been vaccinated during the 
campaign. However, for adults 20-49 years, the reasons for an increase in measles 
seroprevalence after the MR vaccination campaign remain unclear. While this could have been 
due to measles outbreaks, only two cases of laboratory-confirmed measles were reported in 
2015-2016, and measles virus transmission typically peaks October-December when the post-
campaign serosurvey was conducted (Zambian Ministry of Health, 2019a). Alternatively, the 
increase in seroprevalence could be due to selection bias in the serosurveys based on the 
differential age distribution. To address this difference, seroprevalence was directly age-adjusted 
to the 2016 population for Southern Province; however, the increase in measles seroprevalence 
among adults 20-49 years remained. 
Although there were differences in the proportion of females and males between the two 
serosurveys, there were not significant differences in seroprevalence by sex. While there may be 
different immunological responses by sex to vaccination for measles and rubella, it is not clear 
that these would make one more likely to be seropositive (Klein, Marriott, & Fish, 2015; 
Mitchell, 1999). We addressed the differences in sex between the two serosurveys through direct 
adjustments within each age category, based on the 2016 population for Southern Province. This 
should have made the two serosurvey populations comparable. These adjustments did not 
substantially affect the overall seroprevalence point estimates. 
 
Potential confounders 
Another factor that could threaten the comparability between the pre- and post-MR 
campaign serosurveys is confounding by other characteristics, such as HIV infection status. A 
recent review did not find population-level differences in seroprevalence to measles by HIV 
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infection status for adolescents and adults (Loevinsohn, Rosman, & Moss, 2019). However, 
reviews of studies in children found lower seroprevalence to measles among HIV infected 
compared to HIV uninfected children (Mehtani, Rosman, & Moss, 2019; Scott, Moss, Gilani, & 
Low, 2011). A study conducted in our study setting of Southern Province found that HIV 
infected children tended to have lower measles seroprevalence (Sutcliffe et al., 2017).  Similarly, 
our estimates showed HIV infection was associated with a lower measles seroprevalence in 
children. If we captured fewer HIV-infected children in the post-campaign serosurvey than are 
present in the population, this would have inflated our estimate of measles seroprevalence. This 
could have occurred if HIV-infected participants were less likely to participate in the serosurvey 
(Welz et al., 2007). However, there was no difference in participation rates between the two 
serosurveys.  
Our findings also demonstrated HIV-infected participants were more likely to be 
seropositive to rubella. Rubella virus circulation was common before vaccine was introduced, 
with 15 laboratory-confirmed cases in 2015-2016, and 80% of individuals being infected by the 
age of 10 years. Individuals infected with rubella prior to HIV infection have been shown to have 
higher seroprevalence to rubella than age and sex-matched HIV uninfected counterparts (Thomas 
& Aird, 1999). However, we had a small sample size of HIV infected children, none who were 
under 5 years of age and only 6 who were 5-9 years of age. Given we did not test for HIV status 
in the post-campaign serosurvey, it was not possible to confirm whether there was a difference in 
HIV infection status between the two serosurveys. However, sensitivity analyses excluding HIV-
infected participants from the pre-campaign serosurvey did not change the population estimate or 




Differences in specimen collection type 
Another potential explanation for differences in the serosurvey results is specimen type. 
Plasma specimens were collected in the pre-campaign serosurvey, while DBS were collected in 
the post-campaign serosurvey. In the pre-campaign serosurvey, plasma specimens were frozen 
for 2 years prior to testing. However, specimens underwent only one freeze-thaw cycle and thus 
should not have degraded (World Health Organization, 2019). The pre-campaign serosurvey also 
demonstrated high concordance between DBS and serum, as has been reported previously for 
measles and rubella IgG (93%) (Helfand et al., 2001). The post-campaign serosurvey also 
collected a sub-set of serum for 200 participants, which allowed DBS results to be adjusted to 
account for the use of DBS rather than sera for the assay kits (Hayford et al., 2019).  Accounting 
for differential specimen type through these adjustments and subsamples should have made the 
serosurveys comparable in terms of biospecimens collected. 
 
Differences in enzyme immunoassay kits  
An additional consideration for differences in the serosurvey results was the use of 
different EIA kits. EIAs risk misclassification bias due to predefined cut-off values being 
designed for individual patient management rather than population antibody level identification, 
and thus they tend to err towards having higher thresholds for seropositivity (World Health 
Organization, 2015). The high proportion of participants in the pre-campaign centered around 
200 mIU/mL suggest that if the cut-off were too high, this could have resulted in lower observed 
seroprevalence than the true value. Additionally, different EIA kits were used in the two 
serosurveys: the pre-campaign serosurvey used Euroimmun whereas the post-campaign 
serosurvey used Siemens Enzygnost EIA kits. Both kits report similar sensitivity and specificity. 
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The similar quantitative rubella antibody concentration distribution among adults illustrates the 
expected similar seroprevalence among adults measured by both EIA kits. The measles antibody 
concentration range among adults were similar before and after the campaign for adults; 
however, the shift from low-range concentration to high-range concentration was unexpected. 
 
Limitations 
Although several key aspects of the differences between the two serosurveys were 
accounted for through weighting, direct adjustments, and head to head comparison of testing, 
there was still one unexpected result in the findings. The increase in seroprevalence to measles 
among adults 20-49 years old could not be explained with the available data. This could 
represent a difference in who elected to participate in the serosurvey.  Although, these two 
serosurveys were conducted in the same area within a one-year period, we do not believe this 
affected participation, given similar refusal rates in both studies. If this was due to differential 
seropositivity due to HIV infection status, we could not adjust the post-campaign serosurvey, as 
these data were not available. Similarly, we cannot rule out whether this was due to a difference 
in the sensitivity of the measles EIA kits. A lower sensitivity to measles seropositivity in the 
Euroimmun kit has been previously reported ((Tischer et al., 2007). A comparison of the measles 
IgG kits was not possible, as Siemens stopped manufacturing the kit in 2017. 
 
Conclusion 
Two cross-sectional serosurveys were able to demonstrate significant increases in 
seroprevalence from the pre-campaign to the post-campaign for both measles and rubella, 
highlighting the impact of the mass vaccination campaign in 2016. Weighting for survey design 
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selection probability and non-response and direct adjustments to a common age and sex 
population distribution were done to probe if the observed differences in seroprevalence were 
real. While the pre and post-campaign serosurveys had many differences in study design, these 
were mostly addressed to make the serosurveys comparable.  
When serosurveys are collected in separate studies, consideration of the different 
objectives, study design, implementation and laboratory testing should be made to compare 
results. Understanding the variables that could be associated with seropositivity and ensuring 
these are measured could help improve comparability of results. Similarly, collecting sub-
samples of different specimen types and performing head-to-head comparisons if different 
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Table 12. Comparisons between pre and post-campaign serosurvey design 
 ZamPHIA (pre campaign) Nested serosurvey 
(post campaign) 




55 14  
Number of 
households 





























Clusters based on probability 
proportional to size 
Clusters based on 
probability 




based on number needed for 
HIV incidence estimation, 
approximately 30 per cluster 
 
Household based on 
campaign vaccination 
status of children, 12 
per cluster 
In post serosurvey, if 








Children <15 years old in 
every other household, adults 
>15years old in every 
household 
 
Children eligible for 
the campaign (9 
months to <15 years 
old) 
 
In pre serosurvey, if 
households with 
children included were 







All clusters represented 
 
14 of 26 clusters 
In post serosurvey, if 
included clusters were 










All HIV infected individuals; 
Age-specific probabilities 
(22% 0-4, 5-9, 10-14-year 




members home at the 
time of the survey in 
selected households 
In pre serosurvey, if 
HIV infected were less 




In post serosurvey, if 
those present at time of 
serosurvey were more 





Plasma collected from 
venipuncture for participants 
>2 years of age; DBS from 
finger prick for participants 6-
Dried blood spot 
collected from 
fingerpick from all 
participants 
In post serosurvey, if 






23 months and heel prick for 
under 6 months 
Laboratory 
process 
EUROIMMUN ELISA tests Siemens ELISA tests In post serosurvey, if 
Siemens tests are more 
sensitive and have lower 
cutoff, could increase 
seroprevalence* 
Timing Months before vaccination 
campaign 
3 months post 
vaccination campaign 
 
Refusal rates 11% of individuals 
participated in the survey but 
refused blood collection 
12% of individuals at 
enrolled households 
refused to participate 
in the serosurvey 
In post serosurvey, if 
participants had already 
participated in one 
serosurvey may refuse 
second one 
Notes: Table compares methodologies between pre and post serosurveys. Selection bias column 
indicates which serosurvey could be biased based on serosurvey design. All biases are selection 











Age (%)   <0.001 
0-4 20.0 21.7  
5-9 17.4 26.9  
10-14 13.7 17.3  
15-19 12.0 7.4  
20-49 36.9 26.7  
Male (%) 49.8 44.5 0.06 
Males by age (%)   <0.001 
0-4 50.6 56.0  
5-9 50.5 48.5  
10-14 50.5 53.1  
15-19 50.2 46.3  
20-49 48.7 25.2  
Number of people per 
cluster (n(SE)) 24 (1.2) 44 (3.1) <0.001 
Number of people per 
household (n(SE)) 3 (0.1) 5 (0.3) <0.001 
 
Notes: Characteristics presented as weighted percentages to assess if differences remain after 
accounting for serosurvey design, as designated by the p-value. 
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Table 14. Provincial level seroprevalence estimates to measles and rubella pre and post-
vaccination campaign—unweighted, weighted, and direct adjustments 
 
Measles Pre Measles Post Rubella Pre Rubella Post 
Unweighted 59.9% 95.6% 68.5% 97.3% 




















Weighted & direct age 
adjustment 63.0% 95.0% 68.9% 97.3% 


















Notes: Point estimates and 95% logit confidence intervals represent IgG seroprevalence in the 
pre and post-campaign serosurvey. Equivocal results classified as positive. Estimates weighted 
based on survey design.  Direct adjustments made to 2016 Southern Province population 
estimates from the Central Statistical Office. (*) indicates final seroprevalence estimates used as 








Notes: The primary criteria for inclusion in both the pre and post-campaign serosurveys was age. HIV status was part of the selection 
criteria for the pre-campaign serosurvey, and vaccination status was part of selection criteria for inclusion in the post-campaign 
serosurvey. Although sex was not explicitly part of selection criteria, there were differences by sex in who was eventually included in 
the serosurvey. Who is captured in the serosurvey directly affects the seroprevalence estimate generated by the serosurvey. Age and 
sex were collected in both serosurveys, so they were adjusted for in the overall seroprevalence estimates. Because HIV and 
vaccination status were not captured in both serosurveys, they could not be adjusted for in the seroprevalence estimates but were taken 
into account in the selection probability weighting. 
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Figure 14. Relationship of seropositivity and age in the pre and post-campaign serosurveys, polynomial regression spline 
Measles seroprevalence by age (unweighted)   Measles seroprevalence by age (weighted) 
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Rubella seroprevalence by age (unweighted)   Rubella seroprevalence by age (weighted) 
 
Notes: Blue and red lines represent the seroprevalence estimates for the pre and post-campaign serosurveys respectively. Size of 
circles are representative of sample size at each one-year age point. The lines represent the penalized regression spline fit, and shading 
represents 95% confidence intervals around the fit lines. Equivocal results were classified as seropositve. Weighting was done based 





Figure 15. Seroprevalence estimates to measles and rubella by age categories pre and post measles-rubella vaccination campaign—
weighted 
    
 
Notes:  Light and dark blue bars and 95% confidence intervals represent IgG seroprevalence in the pre and post-campaign serosurvey, 














Figure 16. Seroprevalence estimates to measles by age categories and sex pre and post measles-rubella vaccination campaign—
weighted 
Measles 
    
 
Notes:  Light and dark blue bars and 95% confidence intervals represent IgG seroprevalence among females and males, respectively 
within each age category. 95% confidence intervals were not calculated for strata with 100% seroprevalence. Equivocal results 
classified as positive. Estimates were weighted based on survey design. Total is based on weighted and direct adjustment (for age and 




Figure 17. Seroprevalence estimates to rubella by age categories and sex pre and post measles-rubella vaccination campaign—
weighted 
Rubella 
    
 
Notes:  Light and dark blue bars and 95% confidence intervals represent IgG seroprevalence among females and males, respectively 
within each age category. 95% confidence intervals were not calculated for strata with 100% seroprevalence. Equivocal results 
classified as positive. Estimates were weighted based on survey design. Total is based on weighted and direct adjustment (for age and 
sex) to Southern Province population distribution in 2016. Age categories are in years unless otherwise noted. 
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Figure 18. Kernel density plot of IgG antibody concentrations pre and post measles-rubella vaccination campaign for participants by 







Notes: Gray and navy colored lines represent the kernel density distribution of IgG antibody concentrations for participants under 15 
years of age and 15 years of age and older respectively. The pre-campaign concentrations are represented by the solid lines, and post-
campaign concentrations by dashed lines. Values are left-censored based on the lower limit of detection and right-censored based on 
the upper limit of detection. Kernel densities are the distribution of the samples in the corresponding serosurvey with that 
concentration. Red vertical line indicates upper cut-off value for assigning negatives (200 mIU/mL for measles pre serosurvey and 150 




Figure 19. Measles and rubella seroprevalence estimates among HIV infected and uninfected participants by under 15-year olds and 
15 years of age and older 
  
 
Notes:  Light and dark purple bars and 95% confidence intervals represent IgG seroprevalence among HIV uninfected and infected, 
respectively within each age category. Equivocal results classified as positive. Estimates were weighted based on survey design. There 
were 9 HIV infected children under 15 years of age, and 734 uninfected. There were 34 HIV infected adults 15 years of age and older, 




Public Health Importance 
As countries strive for measles and rubella elimination, it may become more important to 
monitor population immunity to ensure high enough levels such that the introduction of virus 
would not result in ongoing transmission. While vaccination coverage has traditionally been used 
as a proxy, serological surveys provide a more accurate estimate of population immunity. 
Concordance between vaccination history and seropositivity has been found to be as low as 
64.3% for measles (Polonsky et al., 2015). Serosurveys are also used by countries, such as 
China, Mongolia, New Zealand, Singapore and Japan, as evidence to present to regional 
elimination committees to monitor progress towards eliminating the transmission of measles or 
rubella (World Health Organization Regional Office for the Wesetern Pacific, 2017). 
When choosing to conduct serological surveys, there are operational questions to be 
answered in terms of implementation. The better that serosurvey operational issues are 
understood and addressed, the more valid population immunity estimates can be derived. Sample 
size, selection criteria, representativeness, and testing methods all factor into the interpretability  
of seroprevalence estimates (World Health Organization Regional Office for the Wesetern 
Pacific, 2017). WHO released measles-rubella serosurvey guidelines that cover the process 
involved in planning, implementing, and analyzing data for serosurveys. While these guidelines 
provide the steps to conducting a serosurvey, they do not address concerns that serosurveys are 
costly and logistically challenging, making them difficult for low and middle-income countries 
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to implement. This study provides information to help guide programs that are planning 
serological surveys for measles and rubella. 
One of the concerns with serosurveys is that there may be high refusal rates to 
biospecimen collection. We found that serosurveys were generally acceptable to the community 
in our setting. Additionally, there was a familiarity with the use of blood for health research, 
likely because serological specimens are collected for HIV and malaria program monitoring in 
this area. We also found that the preferred method of specimen collection in this area was finger 
prick blood collection. Using fingerpick blood collection in our serosurvey nested within a 
vaccination coverage survey may have helped prevent higher refusal rates in areas where 
biospecimens were collected, as compared to areas where they were not collected. Serosurveys 
in Zambia and similar settings should consider the use of fingerpick to make blood collection 
acceptable to the community. 
Previous research on survey participation has used the health belief model to explain 
motivators for participation, which are primarily based on individual level perceptions. However, 
our findings show that the decision to participate in a serosurvey is not solely based on the 
individual being asked to participate, but rather an interplay of individual, interpersonal, and 
structural level factors, as depicted by the socioecological model. Providing information about 
the serosurvey ahead of time can alleviate concerns with serosurvey participation, but it needs to 
be done through a recognizable and trusted vehicle, such as the community health worker.   
A unique consideration for many measles and rubella serosurveys is that they provide 
seroprevalence estimates at a community-level rather than individual-level serological status. 
However, we found that receiving test results was important to participants. Because point of 
care tests are not currently widely available, notifying an individual of their test results would be 
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resource-intensive and require reaching back out to participants after laboratory testing is 
completed. For this reason, we proposed providing community-level feedback, and most 
participants found this approach amenable. Future serosurveys could consider providing 
community feedback through community-wide meetings or notifying community leaders or 
community health workers of the aggregate results to may make serosurveys more acceptable to 
potential participants. Researchers would need to be careful providing feedback, communicating 
clearly that being seropositive to measles or rubella does not indicate the presence of disease, but 
rather protection. This differs from test results provided for HIV and malaria serosurveys, which 
provide disease status and refer for treatment. By contrast, notifying an individual that they are 
seronegative, could have ethical implications. If the individual is in an age group where they 
would be eligible for routine vaccination, they could be referred to the health post. However, 
participants outside the age range who are not protected against measles or rubella virus would 
have to seek vaccination in a private clinic, which could be expensive. Researchers would have 
to consider whether there is an ethical obligation to vaccinate participants who are notified as 
being seronegative and desire vaccination.  
While it is often cited that serosurveys are costly to implement, there is limited empirical 
data on the actual cost of conducting serosurveys.  Our estimate was much lower than the WHO 
estimate of $100,000-$1 million required for serosurveys. We also found that by nesting a 
serosurvey in a vaccination coverage survey, approximately two-thirds of the serosurvey cost can 
be saved. Given that current funding for measles-rubella vaccine introduction requires a post-
campaign vaccination coverage survey, these coverage surveys provide an opportunity for 
specimen collection. Typically, there is a defined budget allocated for the post-campaign 
coverage survey, so programs would need to provide the additional funding for the inclusion of 
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serological specimen collection. If a program has allocated a certain amount for conducting a 
serosurvey, our findings can inform the sampling design based on the proposed budget. For 
example, the level of precision, number of clusters, and number of participants per cluster could 
be calculated to minimize the budget required. In a resource-constrained environment, such as in 
low-income countries, competing health priorities are an issue. If immunization programs can 
use findings from this study to design an efficient serosurvey, it could help advocate for the use 
of serosurveys. 
To minimize cost and improve feasibility, we conducted our serosurveys as subsamples 
of larger surveys: (1) a subset of an HIV serosurvey biorepository and (2) a subset of participants 
in a vaccination coverage survey. While subsampling can make data collection more manageable 
and decrease time required for implementation, it can also make data analysis more challenging. 
Survey design weighting can account for the differential probability of selection of the 
subsamples as compared to the full survey samples. Secondary weighting of the full survey 
samples allows inferences to the target population. However, we found that in comparing results 
from serosurveys with different study designs and sampling methods, there were remaining 
differences. In order to compare the pre and post-campaign serosurveys, we needed to ensure 
seroprevalence estimates represented the same target population. We achieved this through direct 
age adjustment to the population estimated by then census. Because seroprevalence is 
significantly associated with age, serosurveys seeking to compare seroprevalence over time need 
to ensure a similar age distribution in order to be comparable. While the analysis may require 
additional weighting and adjustment, two serosurveys can be used to evaluate the effectiveness 
of a measles-rubella vaccination campaign.  
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The lower than expected seroprevalence to measles found in the pre-campaign serosurvey 
highlights another challenge with measles serosurveys. Similar to our findings, Kenya found that 
children under 15 years of age had only 60% seroprevalence to measles, which rose to 87% after 
a vaccination campaign (Ohuma et al., 2009). The cut-off value set by the commercial ELISA kit 
can have a major impact on the seroprevalence estimate, as demonstrated by the high proportion 
of specimens that fell close to the cut-off value. A European study found that the Euroimmun kit 
used during our pre-campaign serosurvey may underestimate positive measles results by 10%, 
thus underestimating seroprevalence to measles (Tischer et al., 2007).  
We had the unique opportunity to conduct serosurveys prior to and just after the 
introduction of rubella containing vaccine. This allowed us to compare seroprevalence estimates 
from natural infection and vaccine-derived after the campaign in children who were eligible to 
have received vaccination. Interpreting serological results for measles and rubella can be more 
challenging after the introduction of vaccination. Comparing the patterns in the change to 
measles and rubella seroprevalence among children eligible for the campaign and adults who 
would not have been vaccinated helped shed light on some of the discrepancies between the two 
serosurveys. If a country conducts only one cross-sectional serosurvey, patterns of 
seroprevalence could not be ascertained. 
The implications from these findings could also be generalizable to serological surveys 
conducted for other vaccine preventable diseases or infectious agents. For example, reasons 
associated with participation in a serological study may be applicable to other serosurveys. When 
planning for specimen collection in routine surveys such as the DHS or MICS, using DBS and 
making provisions for feedback of testing results could improve acceptability. The community’s 
concern with who gets invited to participate can be addressed through communication messages 
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for a planned survey.  Similarly, understanding the cost associated with increasing survey sample 
size to get more precise estimates by adding additional clusters or additional participants within 
clusters can also be translated to other cluster surveys. Finally, analytic challenges and design 
considerations to compare seroprevalence results from serosurveys using different study designs 
and sampling methods can also be used for serosurveys beyond measles and rubella. Adjusting 
for differential age or sex distributions can help make surveys comparable. These findings can 
help health programs better design serosurveys being planned in the future and how to best use 
serosurveys to monitor population immunity. 
We collaborated with the Ministry of Health to ensure local perspective and priorities 
were being met in conjunction with our research goals and provide capacity building for 
serological surveillance. Furthermore, we used Zambian nationals to conduct all data collection 
and laboratory testing activities, demonstrating the capacity to perform laboratory testing in-
country rather than shipping to reference laboratories. These findings provide a better 
characterization of the operational and feasibility issues of serological surveys to help decision 
makers design and implement serological surveys to meet their programmatic goals. Rather than 
being viewed as costly, logistically challenging endeavors, serosurveys can be more accessible 
for low and middle-income countries. 
Limitations 
Some of the issues with serological surveillance that this research does not directly 
address is the variability in laboratory assays. While we acknowledge the differences in the two 
ELISA kits used for the pre and post-campaign serosurvey, we did not conduct a direct head to 
head comparison of the assays. The potential difference between kits could imply that measles 
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seroprevalence pre-campaign was higher than our estimates; however, there has not been a direct 
comparison done between these two kits. 
Furthermore, the serosurveys used in this analysis provide seroprevalence estimates, 
suggestive of population immunity. However, this is based on predetermined cutoffs defined by 
the ELISA kits, rather than true correlates of protection that could be obtained from plaque 
reduction neutralization tests (PRNT). However, it is not currently possible to conduct PRNT in 
Zambia. The use of commercially available ELISA kits makes serosurveys easier to implement 
in low- and middle-income countries, as not all may be able to perform PRNT. 
The lower seroprevalence of measles among HIV infected children could also have 
affected our seroprevalence comparisons. Other high-HIV settings should consider whether 
testing for HIV should be incorporated into measles and rubella serosurveys, so it can be 
accounted for in the seroprevalence estimates. 
In addition, current laboratory testing technology cannot distinguish whether an 
individual is seropositive to measles and rubella due to vaccination or natural infection. 
Seroprevalence estimates can provide a snapshot of population immunity at a single point in 
time. However, the proportion of seroprevalence due to vaccination programs cannot be 
distinguished from that due to circulating virus. Mathematical modeling may be help tease out 
the likelihood that immunity is vaccine versus infection induced. Repeated serosurveys, such as 
before and after a vaccination campaign, can also help provide information on the proportion of 
seroprevalence attributable to vaccination. 
Finally, the generalizability of these findings in terms of serosurvey design, including 
acceptability considerations and cost, could be limited, as these results represent only one 
country in sub-Saharan Africa. Countries that are not used to household surveys or have higher 
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refusal rates to surveys could be more challenging to implement serosurveys. Similarly, countries 
where there may be more mistrust of government, research agencies, or Western medicine could 
also present challenges to serosurvey participation. Furthermore, Zambia is a setting with high 
HIV and malaria transmission, which is accustomed to blood collection for diagnostic purposes, 
so inferences may vary in other settings. As demonstrated in Paper 1, one-third of caregivers in 
this analysis had participated in previous surveys with specimen collection for HIV/AIDS or 
malaria. The existing infrastructure and laboratory capacity to conduct serosurveys for other 
diseases could also mean our costs underestimate what would be required in other settings. 
Next Steps and Recommendation for Future Research 
Serological surveillance for measles and rubella can be used to answer multiple research 
questions, from estimating burden of disease to predicting the risk of outbreaks. Here we present 
serological surveillance as a tool to identify immunity gaps. These serosurveys created 
immunological profiles in Zambia that can help identify vaccination targets to achieve and 
sustain elimination. The pre-campaign serosurvey demonstrated there were immunity gaps in 
participants under 30 years of age in Southern Province, justifying the need for a mass 
vaccination campaign in 2016 (Paper 3). The post-campaign serosurvey suggests that this 
immunity gap was closed, as seroprevalence at the end of 2016 was above 95%. There have also 
been no laboratory-confirmed cases of measles or rubella from 2016 to date, further suggesting 
that seroprevalence is high in Southern Province. However continued outbreaks in other parts of 
the country mean that Southern Province remains at risk of introduction of measles and rubella 
virus. Therefore, they must maintain high measles and rubella routine vaccination coverage to 
prevent future outbreaks. While this analysis depicted age-specific immunity gaps, serological 
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surveillance can also identify geographic immunity gaps.  Ongoing analyses will use the 
nationwide specimens from the ZamPHIA study to identify spatial immunity gaps and assess 
spatial heterogeneity of measles and rubella seroprevalence. 
Given that these serosurveys were conducted in 2016, mathematical modeling will be 
used with additional data sources, including surveillance and vaccination coverage, to predict 
2019 immunological profiles. These models can help answer questions, such as the level of 
vaccination coverage with measles-rubella vaccine needed to prevent an increase in CRS cases 
after rubella vaccine introduction in 2016. Mathematical models with serological surveillance 
can also better predict the accumulation of individuals susceptible to measles than vaccination 
coverage and surveillance data. We found vaccination coverage data overestimated population 
immunity in the pre-campaign serosurvey, which could have been a factor of underestimated 
target populations, or revaccination of the same individuals. Therefore, serological surveillance 
may provide a more robust data source to predict population immunity gaps. 
This information can be used to better target vaccination efforts (Lessler et al., 2016). For 
example, if a country like Zambia were considering doing a targeted vaccination campaign rather 
than a non-selective blanket vaccination campaign, serosurveys can provide population 
immunity estimates. This could be used to provide information in areas where there is a lack of 
confidence in vaccination coverage data and weak surveillance. Alternatively, if a country is 
considering excluding areas with strong routine immunization and no evidence of circulating 
virus, a serosurvey could verify that population immunity is in fact sufficiently high to provide 
herd immunity. As countries move away from external funding to self-financing, prioritization 
and allocation of resources for activities like vaccination campaigns will become critical. 
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One question that remains for the use of serological surveillance is whether they are cost-
effective in terms of the better immunological profiles being worth the added cost. There is 
variability in the cost of serosurveys based on the sampling parameters, as noted in Paper 2 
where costs could increase $10,000-$30,000 to move from +/-10% to +/-5% precision. However, 
the value of improving precision and the information gained from serosurveys is not clearly 
defined. If serosurveys could be used as noted above, to identify areas that may not need 
vaccination campaigns, they could be costed against the cost of a blanket vaccination campaign. 
Alternatively, serosurveys that identify immunity gaps and trigger vaccination response could be 
costed against what it would cost if an outbreak were to occur. 
Given resource-constrained environments and the high proportion of a serosurvey cost 
spent on collecting specimens (Paper 2), we will be evaluating the ability to use other sources of 
biospecimens to estimate population immunity. The ZamPHIA serosurvey was one example of 
this, which will be costed. Other potential biorepositories being considered include antenatal care 
specimens and the demographic health survey. These biorepositories could identify population 
immunity gaps or provide trends over time, which could signal if population immunity declines. 
We are also working to develop training modules to provide guidance if a country is 
interested in conducting a serosurvey. The costing framework (Paper 2) forms the basis to 
develop a budgeting tool for countries interested in serological surveillance. Lessons learned in 
terms of the acceptability of serological surveillance (Paper 1) will frame considerations for 
social mobilization efforts. Finally, the comparability of serosurveys (Paper 3) will feed into the 
serosurvey design and data analysis portions of the training, such as the need to collect a subset 
of serum or plasma if using dried blood spots, or post-stratification adjustments to improve 
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generalizability of results. These modules will provide capacity building to countries on how 
serological surveillance can guide immunization programs. 
Conclusion 
Serological surveillance can provide countries and program implementers with a more 
accurate population immunity estimate than vaccination coverage or fever rash surveillance.  
However, there are operational and methodological considerations that should be addressed 
when carrying out a serosurvey. Communities are willing to participate in serosurveys, and their 
decisions to participate are based on not only themselves, but also interpersonal factors and how 
the serosurvey is designed. Provisions to address concerns with serosurveys should include 
social mobilization through community health workers. The sampling design and methodology 
can decrease the cost of serosurveys, so they are not cost-prohibitive to low and middle-income 
countries. The difference in methodology between cross-sectional serosurveys can be accounted 
for through data analysis to demonstrate changes in seroprevalence. Immunity gaps identified 
through serological surveillance can then be used to target vaccination. The robust design and 
analysis of serosurveys provides valid population immunity estimates to help countries reach 
herd immunity thresholds to interrupt the transmission of measles and rubella viruses and 




Appendix 1. Glossary of terms 
 
Biomarker—a distinctive biological or biologically derived indicator of a process, event, or condition 
 
Serosurvey – the collection and testing of specimens from a defined population over a specified period of time 
to estimate the prevalence of antibodies against a given etiologic agent as a direct measure of immunity 
 
Seropositivity – detection in biological specimen of an antibody of a specific infectious disease or pathogen 
 
Seroprevalence – the proportion of people in a population who test positive for  antibodies against a specific 
infection or pathogen; it is often presented as a weighted percentage of the total specimens tested 
 
Sero-protection - detection of antibody above a postulated protective threshold 
 
Serosurveillance – serosurveys conducted routinely, periodically or through ongoing collection and testing of 
specimens to assess seroprevalence 
 




Appendix 2. Interview and focus group guides from Paper 1 
 
Interview Guide: Mixed-methods process evaluation of nested serological survey in Zambia 




• Serosurvey supervisors 
• Post-campaign coverage survey supervisors 
• Southern Province post-campaign coverage survey coordinator 
• Laboratory personnel 
• Macha Research Trust personnel 




Mixed-methods process evaluation of the implementation of the serological survey 
 
Specific language from protocol: 
  
The analysis will focus on understanding the strengths and weaknesses of the nested serosurvey. 
Lessons learned in various aspects of implementation of the serosurvey will be examined, such 
as communication, collaboration with the PCES teams, best practices for collecting 
biospecimens, logistical issues and supervision needs.  
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Semi-structured Interview questions  
 
Module I: Supervisors 
 
Note to interviewer: The focus of these interviews is to understand the challenges and best 
practices of the individual during the execution of the nested serosurvey.  We also want to 
identify how this integrated with the overall post-campaign coverage survey.  
 
Core Questions: 
1. Tell me about your experience as a supervisor in the nested serosurvey conducted during 
the post-campaign evaluation survey. 
 
Possible follow-up questions: 
• How did you first learn about/hear about the nested serosurvey in order to apply 
for the position? 
• How were you kept up to date about the progress of implementation? How 
frequently did you communicate with your team?  
 
2.  How were you involved in the preparations for the nested serosurvey? 
 
Possible follow-up questions: 
• How were you involved in the training for the nested serosurvey?  
• What could have been emphasized or modified in training to better prepare your 
team? 
 
3. Could you tell me about your responsibilities during the serosurvey?  
 
Possible follow-up questions: 
• How clearly defined were your responsibilities at the beginning?  Did they change 
over time? (ask as two separate questions with time to answer the first one and then 
ask the second—not both together) 
• How was coordination with the post-campaign coverage survey planning team before 
fieldwork? 
 
4. How did the fieldwork for the serosurvey work for your team? 
 
Possible follow-up questions: 
• What did you think of the time needed to implement the serosurvey? What was 
your typical work schedule? 
• How was coordination with the post-campaign coverage survey teams? 
o Was it clear which households to enroll? (follow-ups: if not, why not? 
What was done to better clarify it during data collection? How could 
future preparations make this more clear?) 




• How was the support provided to your team during fieldwork from the field 
coordinator and staff at Macha? 
o What role did the field coordinator and Macha staff play in helping to 
resolve issues? 
o What were some of the technical issues with the tablets, if any? 
• How well were the teams able to perform blood specimen collection? 
o What were issues you noted in terms of conducting the fingerpick, 
dabbing blood spots? 
o What were issues you noted in terms of collecting liquid capillary blood 
tubes?  
(Probe for differences by age group and possible reasons why) 
o What were any concerns with the storage and transportation of specimens 
back to MRT? 
o Were there any adverse events that could have been foreseen? 
• Were there any issues with the questionnaires? What were they? 
o Were there certain questions that were challenging to interpret? 
o How was data entry with the PCES team? Did they go too fast to capture 
the responses? 
• Was there a clear delineation of roles and responsibilities between the PCES and 
your team? 
 
5. How did the community perceive the nested serosurvey? 
 
Possible follow-up questions: 
• How did you communicate the serosurvey implementation plans ahead of time 
with the community?  
• How did the household react to receiving the teams in their homes for the survey? 
• What were people’s questions when providing consent? 
• Were teams able to collect blood specimens from most household members? 
Were there certain members who tended to refuse more than others? 
• What effect has the nested serological survey had on your opinion of household 
surveys? 
 
6. What lessons have you learned?  We hope to implement future serosurveys; what would 
you do differently next time?  
 
Possible follow-up questions: 
• What were the strengths of the serosurvey?  What went well? How were you able 
to achieve those things that went well? 
• What would have made the serosurvey more efficient? 
• Were any new operational/logistic strategies you put in place to improve 




Module II: Laboratory Personnel 
 
1. Tell me about your experience as a supervisor in the nested serosurvey conducted during 
the post-campaign evaluation survey. 
 
Possible follow-up questions: 
• How were you kept up to date about the progress of implementation?  
• How frequently did you communicate with the field staff?   
 
2. How was the condition of the DBS specimens? 
Note to Interviewer: Give informant plenty of time to address question before asking 
follow-up questions.  
 
Possible follow-up questions: 
• How were specimens transported to you? Please describe any challenges.  
• How timely were specimens received (i.e. within 24 hours, daily, at the end of a 
cluster)? 
• Where there differences in condition of different specimens? 
 
3. How did you provide feedback to the fieldworkers?   
• What was the response of the teams?  
• Were you involved in the fieldwork?  If so, how?  What were your 
responsibilities?  What would you usually have been doing during the time you 
spent on the serosurvey? 
 
4. How was the condition of the liquid capillary blood specimens?   
 
Possible follow-up questions: 
• How were specimens transported to you? Please describe any challenges.  
• How timely were specimens received (i.e. within 24 hours)? 
• Was there any indication of cold chain issues? 
• Were there any opportunities for you to provide feedback to the fieldworkers? 
How did you provide feedback?   
 
5. What were the challenges with specimen processing? 
 
Possible follow-up questions: 
• What were the differences between processing DBS and liquid capillary blood? 
• How were equivocal results treated? 
• What was the technical oversight or support provided? 
• What would have made it easier for you to perform your responsibilities? 
 
6. What lessons have you learned from this serosurvey?  Is there anything that could have 
been done differently? 
 
Possible follow-up questions: 
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• How could we have your role have been better suited to your other 
responsibilities?  
• What things should supervisors and field workers do to ensure proper specimen 







Guide for Discussion with Data Collectors 
 
 
Instructions for Moderators (note that these instructions below and other specific 
instructions will be covered during trainings)  
 
Note taking  
• Take detailed notes to try to capture as much as possible of the discussion. Write down what 
each participant says, trying to capture exact quotes (do not write just summary statements 
from the discussion). Use the recording device provided to ensure you capture the 
details. The facilitator and note taker should write expanded notes immediately after the 
discussion (use the audio recordings). Recordings will be used to complement and be 
compared to the notes. The facilitator will also complement the expanded notes with a memo 
of his/her own observations or recollections  
• Keep a note of “key words” mentioned by the respondents throughout the FGDs that could 
aid in the coding process. 
• Final notes should be typed in a Word document and sent to Andrea Carcelen for analysis. 
 
Using the discussion guide  
• A list of questions is provided as a guide to lead the discussion (see below); however, they 
should not be asked as a questionnaire. The conversation should be allowed to flow naturally, 
and you should try to encourage everyone to voice their opinion. However, discussions on 
each question should not exceed 10 minutes.  Whenever the conversation stops or needs to be 
redirected, you can do so by asking one of the questions that has not been discussed. Before 
the conversation ends, make sure that all the topics in the questions have been covered. 
 
Time management  
• Before the session, arrange for someone (not a participant) to act as time-keeper and make a 
plan for how you will be notified of the time. 
• Manage the time so that each topic is covered, according to the time allowed.  
• Use verbal cues to help keep time with statements like: 
o “There is only time for one more comment.” 
o “This discussion is very important, but in the interest of time we need to end this part of 
the discussion now. We will have time for a final discussion later.” 
 
Agenda 
Welcome, instructions and consent 5Mins  
Ground rules and introductions  5Mins 
Discussion 75 Mins 
Close-out  5 Mins 






Managing Group Dynamics 
 
• The moderator’s major goal is to collect useful information from all participants. 
• Ensure even participation. If one or two people are dominating the discussion, then call on 
others to participate.  
• Ensure only one person talks at a time and there is only one conversation occurring at a time 
(no side conversations). 
• Promote mutual respect, especially when participants disagree. Remind them that everyone 





Welcome, Instructions and Consent (5 minutes)  
 
• Introduction 
Welcome and thank you for agreeing to participate in this focus group. My name is 
_____________, and I’ll be guiding today’s discussion. I work with _______. To assist me 
with this activity are ______________ (names of note takers and observers).  
 
• Purpose of Participation 
As data collectors, you have insight into how the nested serosurvey was executed. We value 
your experience and want to listen to your views and hear your thoughts. The knowledge and 
the information we collect will help us to come up with improvements in implementing 
future serosurveys.  
 
• A comfortable participation for everyone: 
We welcome all your comments, questions, and suggestions. We are eager to hear from each 
of you, but also want you to know that there is no obligation to answer any question that you 
do not feel comfortable answering.  There is no right or wrong answer to the questions I’m 
going to ask, so please relax and feel free to speak openly. 
 
• Informed Consent and Confidentiality 
Before we start, I would like everyone to understand that anything you say here will be kept 
anonymous and that there won’t be any negative effects in terms of your contract or 
payment-based on what you say. This will not affect your payment or review in any way. 
Neither your name nor any information about you will be shared with any other person or 
organizations. No one outside of this group will ever know who said each comment; we will 
only share the summary of your combined responses and some anonymous statements. 
Please understand that there may be different opinions, but there should be mutual respect for 
these differences. I would also like to make sure everyone choosing to be a part of this focus 
group discussion willingly.  
 





(Ask if anyone wishes not to participate, and they will be excused to leave) 
 
(Pause to see if anyone does not want to participate. If anyone does decide to leave, allow 
them to leave the room and then proceed.) 
 
We would like to record our discussion today just to avoid my missing out on anything that 
you talk about during our conversation. My colleague will also take notes during the 
discussion. Does anyone object to that? 
 
(Pause to see if anyone objects.) 
 
Ground Rules and Introductions                                                                               (5 minutes) 
 
• Ground Rules/Guidelines for Discussion:  
 
To make our discussion more comfortable and for it to run smoothly, there are a number of 




Is there anything else we need to clarify? 
Thank you again for your willingness to participate. We know you have all put in a lot of 
hard work for this study, and want to ensure your perspective is heard. 
Well, let’s get started.  OK, I’ll start the recorder. 
 
Discussion       (50 minutes) 
 
Overall 
1. Could you tell me what it was like for you to participate in the nested serosurvey? 
• Everyone’s input is important. 
• Please speak one at a time.  Avoid side conversations. 
• Please speak so that everyone can hear you. [Remember, you are being audio taped. I 
may at times repeat what you say to make sure that your opinion is captured on tape.] 
• Stay focused on the question. [I may need to cut a discussion short because of the 
limited time that we have. So please try to be brief.] 
• It is OK to disagree with another person’s opinion or perspective. [If you dislike 
something or disagree with something that is said, I want to hear about it. However, 
please avoid debating or trying to sway the opinion of others.] 
• Be respectful. 
• If you have your cell phone, please turn it off or put it on silent mode. 
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a. Probe: If you have participated in other surveys or studies, how did this compare 
to previous surveys you have participated in? What was the same/different? 
Preparations 
2. Please tell me what your impression of the training was 
a. Probe: “What could have been emphasized or modified to help you in the field?”  
3.  “Given that the PCES teams were charged with selecting the households, how clear were 
you on which households to enroll?” 
b. Probe: “Was this made clear to you in advance? How could it have been improved?” 
c. Probe: “What is your opinion about the coordination with the PCES teams? What do 
you think facilitated coordination with them?” 
Now we are going to ask you some questions related to the actual implementation of the 
nested serosurvey. 
4. How was the data collection process? 
d. How did the serosurvey affect the PCES activities? (Probe timing of questionnaire, 
data recording and how well they were able to keep up with the PCES) 
e. Were there any issues with the questionnaires? 
f. What type of supervision did you receive? 
5. How was the blood specimen collection process? 
a. What were issues you noted in terms of conducting the fingerpick? What about 
dried blood spots? And if applicable to you, collecting liquid capillary blood 
tubes? (Pause between each question for a response) 
b. How was the storage and transportation of specimens back to MRT? 
c. Were there any adverse events you experienced? 
i. Probe: What strategies would you recommend for avoiding them in the 
future? 
6. What do you think about how the community perceived the nested serosurvey? 
g. (Probe here for perceptions of “acceptability”) 
h.  ( if there are concerns/issues, ask how should the concern(s) be addressed and probe 
for reasons of skepticism or hesitation and proposed solutions) 
i. If it were to be re-done, would you accept your child to participate in the serosurvey? 
Why or why not? 
(probe for “attitudes, risk perception, or structural concerns” that could explain the 
intention to participate)  
7. What lessons have you learned as a surveyor in this study? We hope to implement 
serosurveys in other areas as well, so what would you do differently next time? (probe if 
not already discussed: training, implementation, specimen management, supervision 
8. Is there anything else on these topics that you’d like to share with us today before we 
close? 
Close-out                                                                                  (5 minutes) 
Thank you again for your time today. Please recall that everything said here was confidential. 
This discussion has provided valuable information that will shape the future of serosurvey 
implementation.   
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Appendix 3. Post-introduction evaluation caregiver 

















Time to vaccination clinic: 
 <30 min 
 30-59 min 
 >60min 
 
1. Who influences your decisions about seeking healthcare? [check all that apply] 
 Family (spouse, parents, etc.) 
 Medical personnel (doctors, nurses) 
 Community health worker 
 Chief/headman/religious leaders 
 Other: ____________________________________________________________ 
 
2. Have you received vaccine health information from community health workers (CHWs) 
in your area? 
 Yes 
 No 
 Don’t know 




3. Have you or a member of your family participated in any household health surveys (such 
as for vaccines, malaria, or HIV)? 
 Yes 
 No   [skip to question 4] 
 Don’t know   [skip to question 4] 





 Measles or rubella 
 Other: __________________________________________________________ 
3b. During these surveys, did they collect any bodily fluids (such as blood)? 
 Yes 
 No   [skip to question 4] 
 Don’t know   [skip to question 4] 
3c. If yes: Did you receive the test results? 
 Yes 
 No 
 Don’t know 
3d. How often has your household been asked to participate in blood collection surveys?  
 Never (0) 
 Once (1) 
 A few times (~2-4) 
 Many times (>4) 
 Don’t know 
4. If you were asked to participate in a study that collected a bodily fluid, which would you 
prefer? 
 
4a. Blood draw over finger pricking? 
 Strongly prefer 
 Prefer 
 No preference 
 Do NOT prefer 
 Strongly do NOT prefer 
4b. Finger pricking over mouth swab? 
 Strongly prefer 
 Prefer 
 No preference 
 Do NOT prefer 
 Strongly do NOT prefer 
4c. Mouth swab over blood draw? 
 Strongly prefer 
 Prefer 
 No preference 
 Do NOT prefer 
 Strongly do NOT prefer 
4d. Why do you prefer any one of these? 
 
Blood draw= drawing a teaspoon of blood by putting a needle into a vein in your arm. 
Mouth swab= collecting saliva by rubbing a cotton swab along your gums for one and 
a half minutes. 




5. How likely are you to accept collecting finger prick blood from yourself at home? 
 Very likely 
 Somewhat likely 
 Unlikely 
 Not at all likely 
6. How likely are you to accept having finger prick blood collected from your children at 
home? 
 Very likely 
 Somewhat likely 
 Unlikely 
 Not at all likely 
7. How important is it to you to receive the test results for you or your child? 
 Very important 
 Somewhat important 
 Not important 
 Not at all important 
7a. Would it be acceptable to give summary results to the district health officer instead 
of providing you individual results? (for example, 90% of the people in this village are 
protected against measles) 
 Very acceptable 
 Acceptable  
 Not acceptable 
 Very not acceptable 
8. In your opinion, what are some reasons people may refuse blood collection in their 
households? [check all that apply] 
 The amount of blood collected 
 Being unsure what is going to be done with the blood (why want the blood) 
 Not getting test results 
 Religious beliefs prevent blood collection 
 Fear of needles 
 Safety concerns (for example, that equipment is not clean) 
 Too many researchers collecting blood from community 
 Distrust of the government 
 Other: ____________________________________________________________ 
9. In your opinion, what would make people more likely to allow finger prick in their 
households? [check all that apply] 
 Social mobilization through community health workers (CHWs) 
 Community members trust their CHW 
 Community desire for blood to be collected because interested in test results 
 Community thinks they will get some sort of benefit (medical treatment, money) 
 Community is used to having blood collected 
 Desire to know more about health issues 
 Desire to better society/community 
 Other: ____________________________________________________________ 
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Appendix 4. Post-campaign serosurvey data collection questionnaire 
COMPLETE FOR CHILDREN AGES 9 MONTHS TO 4 YEARS AT TIME OF M-R VACCINATION CAMPAIGN ONLY 
Annex 2D: Cluster Survey Form – ROUTINE EPI SURVEY       
EPI CLUSTER SURVEY FORM - CHILD AGED 9 months to 4 years at time of M-R vaccination campaign 
Cluster #: _______    Cluster name: _____________________              Household #: _______  Date (DD/MM/YY): _____________________  
BIRTH DATE RANGE 
From: 7th December 2011 
To: 19th January 2016 
NAME OF CHILD 
      
Participant ID number         
Birth Date of child: (DD/MM/YY)        
Evidence of immunisation card Yes/No       
BCG0 Date/Yes/No       
      Is scar seen? Yes/No       
OPV0 Date/Yes/No       
OPV1 Date/Yes/No       
Penta1 Date/Yes/No       
PCV1 Date/Yes/No       
Rota1 Date/Yes/No       
OPV2 Date/Yes/No       
Penta2 Date/Yes/No       
Rota2 Date/Yes/No       
PCV2 Date/Yes/No       
OPV3 Date/Yes/No       
Penta3 Date/Yes/No       
PCV3 Date/Yes/No       
IPV Date/Yes/No       
Measles First dose  Date/Yes/No       
Measles Second dose Date/Yes/No       





COMPLETE FOR ALL PEOPLE IN HOUSEHOLD AGES 9 MONTHS AND ABOVE AT TIME OF M-R VACCINATION CAMPAIGN   
PART 2E/F: DEMOGRAPHIC, HEALTH HISTORY, BLOOD COLLECTION – ALL PARTICIPANTS 
 
CLUSTER NUMBER: _______   HOUSEHOLD NUMBER: __________  TODAY’S DATE (DD/MM/YY):   _______________ 





















age in years, 
if 1 year or 
older 









If 1 or more 
pregnancies, 
did you go to 



















   














sufficient = at 












1. Yes     
 
 0. No, never 
1. Yes for 
every 
pregnancy     




1. Yes     
2. Don’t know 
 
0. No 
1. Yes     
 
1.  Refusal before 
blood collection 
2.  Refusal during 
blood collection 
3.  Individual too sick 
to give a sample 
4 . Reached maximum 
number of fingerpicks  
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Appendix 5. Quality control procedures for pre-campaign 
serosurvey laboratory testing 
 
To monitor laboratory testing procedures, approximately 8% of specimens were systematically 
retested on the same plate (7 specimens from each initial plate). In addition, a different 5% of 
specimens (4 specimens from each initial plate) were retested on different plates to assess 
reproducibility. Additionally, two internal control specimens were tested on every plate to 
monitor comparability between plates, in addition to the negative and positive controls included 
in the testing kits. 
 
Figure 1. Measles repeat testing on the same plate (R2=95.6%) 
 
Figure 2. Measles repeat testing on different plates (R2=91.8%) 
 
Notes: Values are IgG antibody concentrations for measles (mIU/mL) during initial and repeated 
test for all specimens repeat tested. Each dot represents one specimen. Red lines designate upper 
cut-off values for negative (200mIU/mL) and equivocal (275 mIU/mL). 






















































Figure 4. Rubella repeat testing on different plates (R2=87.2%) 
 
Notes: Values are IgG antibody concentrations for rubella (IU/mL) during initial and repeated 
test for all specimens repeat tested. Each dot represents one specimen. Red lines designate upper 






































Appendix 6. Pre-campaign measles serosurvey laboratory 
testing with alternate cut-off value 
 
Given the lower sensitivity of the Euroimmun measles kit compared to other ELISA kits, we 
considered lowering the threshold for equivocals down to 150 mIU/mL. The results 
demonstrated that there was increase in overall measles seroprevalence in the pre-campaign frp, 
64.2% to 82.0% with the new cut-off. By age-category, there is no longer a statistically 
significant difference in the pre and post campaign in the age categories older than 15 years of 
age, as would be expected since they were outside the range of the vaccination campaign. 
 
Table 1. Seroprevalence to measles by age category in the pre and post-campaign serosurveys 
using 200 mIU/mL and 150 mIU/mL cut-offs in the pre-campaign serosurvey 










































Note: Value indicates population seroprevalence estimate in that age category and 95% 
confidence interval. (*) indicates whether there was a statistically significant difference between 




Figure 1. Relationship of measles seropositivity and age in the pre and post-campaign 
serosurveys, polynomial regression spline 
  
Notes: Light blue and dark blue lines represent the seroprevalence estimates for the pre and post-
campaign serosurveys respectively. Size of circles are representative of sample size at each one-
year age point. The lines represent the penalized regression spline fit, and shading represents 
95% confidence intervals around the fit lines. Equivocal results were classified as seropositve. 
Weighting was done based on survey design. 
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